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There is discordance in the vitamin D literature between correlational studies, 
which show an association between higher vitamin D exposure and good health, and 
randomized controlled trials of vitamin D supplementation, which are inconclusive. I test 
the theory that this discordance is due to false assumptions about how vitamin D affects 
human health. I use the method of systematic review and meta-analysis—accepting only 
experimental studies that supplement with the animal version of vitamin D, D3, not D2 or 
vitamin D metabolites or analogues, as well as accepting only studies with daily rather 
than less-frequent but larger doses—to show that daily vitamin D3 supplementation has a 
statistically-significant beneficial effect on blood pressure and markers of diabetes. Using 
nationally-representative correlational data, I also demonstrate that the health disparities 
in blood pressure, if not diabetes, will be eliminated only with new health policies 
dedicated to health education on the vast nutritional difference in vitamin D status 
between black and white Americans. As a part of this dissertation, I also developed an 
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I – INTRODUCTION 
Those of us in the field of health education look to Healthy People, the public 
health plan of the United States, to guide our efforts. Updated every ten years, Healthy 
People provides “science-based national objectives for improving the health of all 
Americans.” One of the plan’s four overarching goals is to “achieve health equity, 
eliminate disparities, and improve the health of all groups.” Yet nowhere among the over 
1,200 goals of the current plan, Healthy People 2020, will you find the phrase vitamin D 
(U.S. Department of Health and Human Services, 2010). 
I became interested in vitamin D, the sunshine vitamin, during the first semester 
of my graduate studies. That is when I read this illuminating paragraph in “The Fat 
Soluble Vitamins: A, D, E, and K” in my Introduction to Nutrition textbook: 
   The pigments of dark skin provide some protection from the sun’s damage, but 
they also reduce vitamin D synthesis. Dark-skinned people require longer sunlight 
exposure than light-skinned people: heavily pigmented skin achieves the same 
amount of vitamin D synthesis in three hours as fair skin in 30 minutes (Whitney 
& Rolfes, 2008, p. 380). 
The paragraph made me wonder whether there was a causal relationship between health 
disparities, the elimination of which is an overarching goal of my profession, and 
disparities in vitamin D status. 
Previous Research 
During my graduate studies, my research colleagues and I have published four 





Weishaar, Rajan, & Keller, 2016; Weishaar & Vergili, 2013), all of which were based on 
correlational, cross-sectional data from the U.S. National Health and Nutrition 
Examination Survey (NHANES). Every year, NHANES randomly samples about 5,000 
Americans to obtain data about the health and diet of the U.S. population. In two-year 
cycles, beginning with 1999-2000, the results of the NHANES questionnaires, 
examinations, and laboratory assays are released, carefully hiding any personally-
identifying information. NHANES uses a research design called a complex survey (Zipf, 
Chiappa, & Porter, 2013), which requires special analysis software, but which provides 
nationally-representative data. While a graduate student, I learned how to use a version of 
this software written in the statistical programming language R. 
Our first article used linear regression to show that vitamin D status moderates the 
disparities in self-rated health between racial-ethnic groupings (Weishaar & Vergili, 
2013). The second implemented a formula published by other researchers to show that 
the recommended dietary allowance of 600 international units (IU) per day for vitamin D 
was not high enough for children with darker skin colors or heavier body weights 
(Weishaar & Rajan, 2014). The third showed that the effect of age, which is the only 
variable factor in the current recommended dietary allowance for vitamin D (400 IUs a 
day for those less than 1 year old; 600 IUs a day for those from 1 to 70; 800 IUs a day for 
those over 70), are inconsequential compared to the effects of skin color and body weight 
(Rajan et al., 2016). The fourth presented the probability of vitamin D deficiency by body 
weight and skin color in the U.S. population age 6 and older at three different deficiency 
targets—because even the definition of vitamin D deficiency is currently contentious 





Vitamin D status has been associated with childhood rickets and adult bone 
disease since vitamin D’s discovery about 100 years ago. Since then, however, 
researchers have realized that bone disease is only the beginning of vitamin D’s story. 
Inside the nucleus of cells, genetic processes use DNA to make the proteins of life. These 
processes are controlled by nuclear receptors, which up- or down-regulate the genome’s 
production of specific proteins in response to signaling molecules. Different organisms 
have different numbers of these receptors, which respond to a variety of substances, some 
of which are produced inside the organism and some of which are obtained externally (in 
humans, through the diet). Human cells have 48 nuclear receptors, one of which responds 
specifically to at least three vitamin D metabolites, each regulating, for the most part, 
different genes (Tuohimaa et al., 2013). Vitamin D’s signaling function appears to control 
at least two percent of the human genome and has been associated with a wide range of 
human diseases and conditions (Holick, 2007). 
These effects are profound enough to be seen in human evolution. Following an 
idea first proposed in 1934 (Murray, 1934) and resurrected in the 1960s (Blois, Blum, & 
Loomis, 1968; Loomis, 1967), Nina Jablonski, an anthropologist, suggests that as human 
populations moved away from the equator, individuals in those populations with lighter 
skin had vitamin D levels closer to those of the ancestral population and consequently 
better health. These disparities, over many generations, led to the evolution of the 
spectrum of human skin colors we see in human populations today (Chaplin & Jablonski, 
2009; Jablonski, 2004; Jablonski & Chaplin, 2000; Yuen & Jablonski, 2010). According 
to Jablonski (2012), “The array of colors found in human skin is greater than that seen in 





Jablonski’s theory is supported by NHANES data. Vitamin D concentrations 
average 17 ng/ml in non-Hispanic blacks, 21 ng/ml (26% higher) in Mexican-Americans, 
and 28 ng/ml (62% higher) in non-Hispanic whites (Weishaar et al., 2016). In terms of 
the benefits of dark skin, the most dangerous type of skin cancer, known as invasive 
melanoma, is 25 times more likely in U.S. whites than in African-Americans (U. S. 
Department of Health and Human Services, 2014).  
Rural residents of Ghana living near the equator (6° N) have an average vitamin D 
concentration of 30 ng/ml, which is higher than any group in the U.S. (Durazo-Arvizu et 
al., 2014). Traditionally-living people in east Africa (4° S) have an average concentration 
of 46 ng/ml (Luxwolda, Kuipers, Kema, Dijck-Brouwer, & Muskiet, 2012). This is our 
best available estimate of vitamin D concentrations over the course of human evolution. 
Another anthropologist, Kathleen Fuller, was the first to turn the theory of the 
evolution of human skin color around and look at it from a health perspective (Fuller, 
2003). From that perspective, the theory implies that health disparities will be found in all 
populations with diverse skin colors. Where sunlight is intense, those with lighter skin 
will be at a disadvantage; where sunlight is less intense, those with darker skin will have 
poorer health. Fuller says, “Humans are biological organisms and the presence of disease 
indicates a maladaptation between the individual human organism and its environment” 
(p. SR9). Yet by almost trivial changes to the environment, using sun protection and 
vitamin D supplementation, it should be possible to prevent these sunlight-related 
diseases. 
There are dozens of articles in the literature supporting these relationships, which 





have yet to be recognized or taken seriously either by those who study health disparities 
or by those who set public health policy in the United States. The biggest barrier to 
acceptance of these theories in U.S. health policy is discordance among the conclusions 
of systematic reviews and meta-analyses of randomized controlled trials of vitamin D 
supplementation. There have been hundreds of randomized controlled trials looking at 
various health and performance effects of vitamin D supplementation. There is also 
already an abundance of systematic reviews and meta-analyses combining groups of 
these trials. But their results do not agree. 
 The resulting controversies reduce the confidence that physicians, nutritionists, 
and public health professionals have when they educate their patients about vitamin D. To 
educate others about health you have to know something about the causes of health, and 
vitamin D supplementation is a great example of an area in which confusion and 
controversy currently reign.  
Conceptual Framework 
I propose that the discordant results of these reviews are due to three 
unappreciated sources of heterogeneity – the form of vitamin D given as a supplement; 
daily versus less-frequent but larger bolus dosing; and differences from study to study in 
the baseline vitamin D status of the participants. 
Existing reviews typically assume that vitamin D2 and vitamin D3 are equally 
effective, but this view has been challenged. Vitamin D2, also known as ergocalciferol, is 





produced by plants and animals (Japelt & Jakobsen, 2013). Vitamin D has a long 
evolutionary history going back to the development of cells with a nucleus.  
Long before vitamin D was discovered, it was known that certain foods–
particularly cod liver oil–would cure rickets, a disease known since antiquity. Vitamin D 
was discovered in 1922 after a process for destroying the vitamin A in cod liver oil was 
developed and the resulting oil continued to cure rickets in rats. About the same time, 
another traditional cure for rickets, fresh air and sunshine, was confirmed by curing 
rickets in children using exposure to ultra-violet light (UV) from quartz-mercury lamps. 
Soon researchers discovered that UV radiation would also give antirachitic properties to 
many foods. Then they discovered that a fungal steroid derived from ergot and called 
ergosterol was the substance that picked up antirachitic properties when exposed to UV 
light. By 1931, several research groups had purified and crystallized the resulting product, 
which they named ergocalciferol (Wolf, 2004).  
But plants and animals, unlike fungi, do not produce ergosterol. Even today many 
experts think that plants, like fungi, produce vitamin D2; this misconception is a result of 
fungal contamination of plants and high concentrations of ergosterols in fungi (Japelt & 
Jakobsen, 2013). It took until 1937 to discover that in animals the precursor that gains 
antirachitic properties when exposed to UV light is a form of cholesterol. The resulting 
substance was named cholecalciferol or vitamin D3.  
Another 50 years passed before reports appeared in the literature suggesting that 
vitamin D2 was not as effective in humans as vitamin D3 (Tjellesen, Hummer, 
Christiansen, & Rodbro, 1986). By 2006 Houghton and Vieth argued in the American 





appropriate for supplementation or fortification of foods” (Houghton & Vieth, 2006, p. 
696). However, now, over a decade later, most medical, nutritional, and public health 
professionals continue to assume that vitamin D2 and D3 are equivalent. For example, in 
the U.S., vitamin D supplements available by prescription (rather than over-the-counter) 
continue to be compounded with vitamin D2 rather than D3. Moreover, systematic 
reviews and meta-analyses of vitamin D trials typically make no distinction between the 
two. 
The existing reviews also tend to assume that vitamin D supplements will be 
equally effective in either small daily doses or in larger, less-frequent bolus doses. The 
human liver rapidly converts the parent form of vitamin D to 25-hydroxyvitamin D 
(25(OH)D). Consequently, assays to determine vitamin D status are based on serum 
concentrations of 25(OH)D, which will rise no matter how researchers split the vitamin D 
dose, leading to the assumption that daily and bolus dosing are equally effective.  
However, after the liver converts the bolus dose to 25(OH)D, there is little 
remaining parent vitamin D in the serum. The liver-made 25(OH)D primarily ends up 
attached to vitamin D binding protein, an albumin-like blood protein. This 25(OH)D, 
which can be removed from vitamin D binding protein and further metabolized by the 
kidney, has a major role in calcium balance. However, the primary form of vitamin D 
absorbed by cells throughout the body for DNA signaling is likely the parent form (Hollis 
& Wagner, 2013). Cells outside the calcium-balance system may not depend upon the 
25(OH)D at all. If this theory is correct, daily dosing, which maximizes the daily levels of 





The third source of heterogeneity is differences in the baseline vitamin D status of 
trial participants. Vitamin D supplementation studies are different from drug studies in 
that drug studies can assume that participants have not received the drug from any source 
other than the intervention. This is simply not the case with vitamin D. In addition to the 
intervention dose, both the control and intervention groups are exposed to vitamin D from 
sunlight and dietary sources. There can be additional differences in 25(OH)D status 
related to body weight and other personal, cultural, and geographic characteristics of the 
study’s population. Randomization, in expectation, accounts for these differences within a 
single study, but differences between studies in the baseline vitamin D status of the 
subjects is typically an unanalyzed source of heterogeneity in vitamin D meta-analyses. A 
study with subjects having very low baseline vitamin D status may show a larger effect 
than a study using the same dose, but with subjects having a very high baseline vitamin D 
status. As a measure of total exposure to vitamin D, 25(OH)D status should be a better 
predictor of effect than dose. 
Moreover, if serum availability of the parent form of vitamin D is the actual 
determinant of beneficial effects, serum 25(OH)D status should be understood as a 
biomarker for vitamin D exposure rather than a biomarker for effect. Nonetheless, as a 
biomarker of total exposure, 25(OH)D status should be a better indicator of effect than 
dose, which accounts for only a part of total exposure. Study-to-study differences in 
vitamin D exposure, as measured by the mean 25(OH)D status of the control group at 
outcome, is likely to be a third source of important heterogeneity in meta-analyses of 





In addition to issues with heterogeneity, many of the vitamin D systematic 
reviews show a trend toward effectiveness, but that trend is not statistically significant 
because of the limited number of trials for any particular outcome. However, the health 
effects of vitamin D may be homogenous enough to combine trials with different health 
and performance outcomes in a single meta-analysis. This would address the statistical 
problem posed by the limited number of trials for any single outcome. Generalizing the 
outcome has a long history in meta-analysis; the first meta-analysis ever done mixed 
trials with various outcomes of psychotherapy (Smith & Glass, 1977). 
The existing systematic reviews and meta-analyses, for the most part, accept trials 
of any form of vitamin D (D2, D3, their metabolites, and patent-protected analogues, with 
and without calcium supplementation) and trials of both daily supplementation and 
supplementation with less-frequent but larger bolus doses. Standard practice also restricts 
each meta-analysis to a single disease or condition, even though vitamin D status 
correlates with a wide range of beneficial effects on human health and performance. This 
restriction limits the number trials available for analysis. The literature’s discordant 
results may be largely due to these issues. 
Systematic Reviews and Meta-Analyses 
In order to test my hypothesis about the discordant results of systematic reviews 
and meta-analyses of vitamin D supplementation, it became apparent I would have to 





systematic review and meta-analysis of experimental data resulting from randomized 
controlled trials (RCT). 
A systematic review is a special type of scientific literature review. Systematic 
reviews, which can be done with or without meta-analysis, are designed to control 
researcher bias (Chalmers, Hedges, & Cooper, 2002). Instead of allowing a reviewer to 
select only literature that the reviewer agrees with, a systematic review requires the 
reviewer to explicitly state the strategy that will be used to discover studies (with the goal 
of including all relevant studies in the analysis). The reviewer must also explicitly state 
the criteria that will be used for including and excluding discovered studies from the 
review. Ideally, before the actual review process begins, the reviewer must detail this 
strategy and these criteria, along with additional information about the proposed review 
process, in an online registry. If any changes are made to the proposed process, they must 
be explained as part of the review itself.  
A meta-analysis, which can be done with or without a systematic review, brings 
statistical precision to the process of examining a group of studies and determining what 
they mean (Chalmers et al., 2002). Before meta-analysis, reviewers often evaluated the 
literature by counting the number of studies with significant and non-significant results 
and declared the truth resided in the group with the larger count. But statistical 
significance is highly dependent on the number of subjects in a study; any study with 
enough subjects will be statistically significant. The statisticians who developed meta-
analysis realized that what was important was not so much the statistical significance of 
the study’s effect but the size of the effect (Glass, 2015). Statisticians developed 





study. They also developed methods for weighting effect sizes to determine the size or 
strength of the weighted-mean effect and the statistical likelihood that future studies 
would have a similar result. Meta-analysis also involves measuring whether the studies 
all have similar results, which is called homogeneity, or whether the results of the studies 
are heterogeneous, or statistically dissimilar. When the results are heterogeneous, meta-
analysis provides statistical methods to examine the heterogeneity and to possibly 
discover what is driving the differences between the studies. 
A combined systematic review and meta-analysis of randomized controlled trials 
is currently the best practice for determining whether an intervention has a causal effect, 
rather than just a correlational relationship. As I considered doing a structured review and 
meta-analysis of my own, I hesitated because these are large projects, usually done by an 
entire team of analysts, which involve searching the literature to find studies, reviewing 
them for eligibility, extracting their results and judging their quality, statistically 
combining the results, and writing a report of the results. And every step by every team 
member ought to be tracked and documented.  
With the encouragement of my advisors, I decided to create the software for doing 
a structured review and meta-analysis. The statistically-intense meta-analysis software I 
would need had already been written by others and was easily available in open-source R 
packages. What was missing was a good system for doing the systematic review. In terms 
of my time, the bulk of this dissertation involved combining open-source software 
packages with software I wrote myself, followed by getting it all running in the cloud so 
that anyone with a web browser and the link, app.open-meta.org, could access the 





Software like this is never finished, but as it became possible to do a bona fide 
systematic review and meta-analysis using the application, I completed two 
demonstration reviews on vitamin D supplementation. These reviews used criteria based 
on my conceptual framework, which requires daily vitamin D3 supplementation. The first 
of these reviews was on the effect of vitamin D3 on blood pressure and the second was on 
its effect on markers of diabetes. 
Specific Aims 
In the context of the specific aims of this dissertation, a beneficial effect refers to 
a weighted-mean effect size, from all available studies, favorable to better health, with a 
95% confidence interval that does not include the no-effect value. 
1. To develop a health education-focused, multi-user, open-source 
application for continuous online updating and replication of systematic 
reviews and meta-analyses. 
2. To use this application to calculate the best current estimate of whether 
daily vitamin D3 supplementation has a beneficial effect on systolic blood 
pressure. 
3. To use this application to calculate the best current estimate of whether 
daily vitamin D3 supplementation has a beneficial effect on markers of 
diabetes, such as fasting glucose and fasting insulin, glycosylated 





(HOMA-IR) and β-cell function (HOMA-β), and the quantitative insulin-
sensitivity check index (QUICKI). 
The next three chapters discuss each of these three specific aims, in order, 





II – THE OPEN-META APPLICATION 
Health professionals rely on systematic reviews and meta-analyses to determine 
appropriate and beneficial health policies. Organizations such as the Cochrane and 
Campbell collaborations and the Agency for Healthcare Research and Quality were at the 
forefront of developing the processes and methods used to create the systematic review 
and meta-analysis. These methods have also been adopted in other fields, such as 
nutrition and education. 
PRISMA: Best Practices for Systematic Reviews 
The best-practice procedure for conducting these studies has been documented in 
a body of work called Transparent Reporting of Systematic Reviews and Meta-Analyses, 
or PRISMA (PRISMA, 2015). (There are similar standards for reporting on the results of 
controlled trials called CONSORT (CONSORT, 2010).) The PRISMA Statement 
(Liberati et al., 2009) was originally published in 2009 and includes a checklist of items 
that should be included in the published report of a systematic review and meta-analysis, 
as well as an example flow diagram. A second related document, called the PRISMA 
Explanation and Elaboration (Moher, Liberati, Tetzlaff, & Altman, 2009), provides in-
depth information on the items in the checklist. 
In 2015 a similar checklist was published under the auspices of PRISMA, called 
PRISMA-P (Moher et al., 2015), which describes the information that should be included 





and published online before the work begins (PROSPERO, 2012). Its goal is to reduce 
researcher bias by forcing the research team to commit to inclusion criteria and analytical 
methods before beginning the study, as well as to make sure the team collects all of the 
information that PRISMA requires in the final report. PRISMA-P also has an explanation 
and elaboration document (Shamseer et al., 2015) that provides additional information 
and examples of how to complete the protocol.  
The PRISMA documents, procedures, and protocols define a systematic process 
for creating systematic reviews. What is missing is a systematic, multi-user, computer 
application that embodies that process. Research teams typically try to bring the process 
to life with check sheets and spreadsheets, but so many sheets result in a tedious and 
error-prone project. Reducing the tediousness typically results in more errors. Reducing 
the errors typically results in more tediousness. 
PRISMA and the Open-Meta Application 
The Open-Meta application was created to provide an online, structured process 
for a team of researchers who are creating a PRISMA-compliant systematic review and 
meta-analysis. It is intended to provide a team with support across the entire process from 
protocol development to publication. It is intended to be freely available and to encourage 
transparent crowd-sourced research. The Open-Meta application takes care of much of 
the tracking and tedious work of a systematic review while providing everything needed 
to meet the PRISMA protocol and reporting guidelines. 
In theory, anyone can use the Open-Meta application to start a project. Anyone 





join the project. The project’s principal investigator has the ability to approve project 
membership and can grant permissions to each project member specifying what that 
member can contribute to the project. As the project progresses, anyone can see the 
current project status but only project members can complete tasks and move the project 
forward. Multiple people can work on a project simultaneously from any geographic 
location that has web access. 
Methods 
How to Build an Application in the Cloud 
In addition to being an online store, Amazon, thorough its Amazon Web Services 
subsidiary, sells online computing resources. The Open-Meta application runs on an 
internet-linked computing resource provisioned by an Amazon service called Lightsail. 
When I set up the computing resource, I selected what operating system and major 
software components it would use. This basic set of components is called a stack. 
One of the most popular stacks is called a LAMP stack; it consists of the 
components typically used to run a content management system, such as WordPress or 
Wikipedia. The LAMP stack consists entirely of open-source software. The L is for the 
Linux operating system, the A for the Apache web server, the M for the MySQL database, 
and the P for the PHP programming language. 
The Open-Meta application is built on a slightly different stack that I call LEMRS. 
The L is for Amazon’s version of Linux, the E is for nginx (pronounced “engine-x”), 





The M is still for MySQL. The R is for the R programming language. And the S is for 
Shiny, software that provides the ability to use the R language to display web pages that 
users can interact with. The Open-Meta application currently runs R, version 3.4.1 (R 
Core Team, 2017), shiny, version 1.2.0 (Chang, Cheng, Allaire, Xie, & McPherson, 2018) 
and a variety of add-on packages, including all of the packages in the tidyverse (Wickham, 
2017). 
The Open-Meta application is configured to have the nginx server deal with any 
URL request except those that link to an imaginary app folder. When nginx sees a URL 
that requires access to that folder, it is configured to pass the request to the Shiny Server, 
which is running the Open-Meta application. The Shiny Server will start a new session on 
the Amazon resource specifically for the device that has requested the URL (typically a 
person using a web browser) and pass anything in the URL after /app/ to the new session. 
Imagine for the moment that the requested link is: http://app.open-meta.org/app/?help. 
How a Simple Page Works 
At this point, control passes from the LEMRS stack to the Open-Meta software 
that I have written in R, which, for the most part, links together R packages and other 
open-source technology written by others. For example, the look-and-feel of the site is 
based on a Bootstrap 4 theme called Dashboard (Bootstrap Team, 2017).  
Briefly, my software asks the user’s web browser if it has an Open-Meta 
sessionID cookie. If it does, the software looks up that sessionID in a MySQL table to 
determine whether the request has come from a known, logged in user or from the great 





including the permission level the user has. Then the software looks to see if the 
requested page, help, is a valid page. Back when the Open-Meta application started up, 
one of the things it did was load a table of all the valid pages from MySQL and store that 
table in memory. The requested page, help, is in this list, so it is valid. 
Next the software looks in the same table to see what permission level is needed 
to view that page and compares it to the user’s permission level. Since anyone can see the 
help page, the software next loads a file called Help.R that has the additional code needed 
to display the page. The code in the file sends the page as HTML to the user’s browser. 
The user sees the help page. This all happens in computer time, so to the user it appears 
pretty much instantaneous. 
On the help page there is a short message from me and a form for sending me an 
email. It looks like Figure 2.1. 
At this point our Shiny session is still running, but it doesn’t have anything to do. 
If the user fills in the form, the user is actually interacting with the web browser software 
on the user’s own device, not with the Open-Meta software. (Technically, Shiny gives our 
software the ability to monitor exactly what the user is doing down to any mouse 
movements or keystrokes that occur inside the browser window, but that is typically way 
more information than we want to know.) However, if the user clicks one of the buttons 
or links I have circled in red in Figure 2.1, our session will get a buzz and will look to see 
what the user clicked on. 
If the click was on Home, Register, Login, Help/Contact, or Cancel, our session 
will send a message to the browser telling it to request a different URL. Our current 





know who the user is and whether the URL is a valid page. Also keep in mind that several 
users can be doing this at the same time, each with a separate and distinct session. 
Figure 2.1. Open-Meta help page with links circled in red. 
 
On the other hand, now imagine that the user clicked the Send button in Figure 
2.1. In this case our help page code gets the content the user has entered into the email 
form and checks to see if it is valid. If it is not, we send a message to the user’s browser 
saying so. This looks like Figure 2.2. 
If, on the other hand, the user’s input is valid, the code puts it all in a specific 
format for email and sends it, with a signature validating that Open-Meta is sending it, to 





as with the other links on this page, will tell the browser to go to a different URL, which 
will end this session and start a new one. 
Figure 2.2. Open-Meta help page after user clicks Send with invalid input. 
 
One final detail. Note that in Figure 2.1 no one is logged in. If someone was 
logged in, the Register link would have their login name and the Login link would say 
Logout. There is a sample of what the page would look like in Figure 2.3. 
Not only are the links at the top right slightly different because the user is logged 
in, note that the form is no longer asking for the user’s email address. That is because the 
program knows the email addresses of all users and we know who this user is. So there is 





administrator, there would be no reason to send email to oneself, and the Help/Contact 
link would instead say Admin and lead to pages where administrative information is 
displayed and administrative options can be set. 
Figure 2.3. The Open-Meta contact page with a logged in user. 
 
The Help.R file is one of the simplest in the Open-Meta application and consists 
of about 60 lines of code and comments. The Open-Meta page table currently lists 26 
pages. There are about a dozen additional shared helper files that various pages load 
when needed. Most of these files have about 250 to 400 lines of code and comments; the 






While anyone can view content in the Open-Meta application, in order to do 
anything else, the first step is to register for an account. To register, the user must provide 
a user name new to the system, a password, and a working email address. During the 
registration process, an email is sent to that email address with a numeric code that must 
be entered to complete the registration. This ensures that the email address is valid and 
that it belongs to the person who is registering. Passwords are stored in the database in an 
encrypted format using an R package called bcrypt (Ooms, 2018). 
Initial Screens 
Once a user has registered and logged in, the screen looks like Figure 2.4. In 
addition to the links related to the user’s account and help at the top right, there are now 
links in the middle of the page that display the projects the user has joined or started (My 
Projects), all the current active and completed projects (Active Projects and Finished 
Projects), and a link that allows the user to create a new project (Start a Project). 






If the user clicks on Start a Project, the screen in Figure 2.5 appears. Here the 
user enters a name for the project. As on the help page, there is additional text on this 
page in a yellow box that explains to the user what will happen. Boxes like this are used 
for additional information throughout the application. 
Figure 2.5. The screen for beginning a project. 
 
After the user clicks Start a Project, behind the scenes a new MySQL database is 
created for this project. But the user is taken to a screen for entering the project’s protocol. 
This page follows the requirements of the PRISMA-P protocol for systematic reviews 
and meta-analyses. There are over 30 individual sections on this page that must have text 
entered into them before other project features are activated. Among these are the exact 
criteria for inclusion for participants (P), interventions (I), comparisons (C), outcomes 





Each section of the protocol includes instructions for that section based on the PRISMA-
P requirements. Often the instructions include references to the PRISMA-P documents. 
In addition to the page for entering the project’s protocol, at this stage there are 
two other menu items for those who are not project members. One is Join and the other is 
Contact. Joining a project allows the user to receive emails sent by the Principal 
Investigator to the project team and allows the PI to give that user additional abilities 
within that project by changing the user’s role. Contact provides a form for sending an 
email to the PI. Those who are already project members see only the Contact menu item, 
except for the project’s Principal Investigator or Project Administrator, for whom this 
menu item is Members & Settings. 
Project Members and Settings 
The Members & Settings page is shown in Figure 2.6. On this page there are three 
submenu items, Project Members, Customize Data Collection Forms, and Activate 
without Protocol. That third item provides a way to play with the Open-Meta system 
without writing a protocol. The second provides a way to customize and enhance some of 
the Open-Meta forms that collect data. The first allows the PI to change user roles and to 
email individual project members or all the project’s members at once. 
The Open-Meta system has the following user roles for each project: 
Non-Member: Anyone can view most pages of any project. 
Observer: Will also receive emails sent to All Members of the project. When users 





Reviewer: Can also review citations to decide if they pass or fail the project’s 
inclusion criteria. 
Investigator: Can also extract data from studies and create analyses. 
Researcher: Can also enter searches. 
Principal Investigator, Co-Principal Investigator, and Project Administrator: Can 
also access the project's Members & Settings and Publish pages. (These roles have all 
available permissions.) 
Figure 2.6. The Members & Settings page, available to Principal Investigators. 
 
After the protocol is complete (or the project has been activated without a 
protocol), the menu items become Protocol, Search, Review, Extract, Synthesize, Publish, 
and either Contact or Members & Settings, depending on the user’s role. At this point 





Protocol page does allow the PI to add amendments and to provide references for 
publications resulting from the study. 
Search for Studies 
The next step in a systematic review is to search in academic databases for 
publications that report the results of studies that meet the project criteria. Because the 
goal is to find all the relevant studies, the search terms used at this stage typically also 
find many studies that meet some, but not all, of the project’s criteria. In the field of 
health, the National Library of Medicine provides a database that is publically available, 
PubMed (U.S. National Library of Medicine, 1997), and Open-Meta can search for and 
automatically download the associated data from citations found on PubMed. However, 
most, if not all, other academic databases are not available directly to the public, but must 
be accessed through a research library. The Open-Meta app is not able to directly search 
and download from these other databases. Instead, the researcher must do the search in 
the academic database and download the references as if they would be loaded into 
reference management software such as EndNote. But instead (or in addition), the user 
uploads the file to Open-Meta. 
Figure 2.7 shows a live search of the PubMed database for the search terms 
(vitamin D[Title/Abstract]) AND “systematic review”[Publication Type]. Above the 
bottom comment box you can see that the search found 149 citations, all of which have 
abstracts and PubMed IDs (PMIDs), and 131 of which have document object identifiers 
(DOIs), which help to both indentify duplicate articles and to find articles online. 





For example the researcher might decide to change the search terms. Once the 
search is processed it can no longer be changed and the references cannot be deleted from 
the project. 
Figure 2.7. Live search of the PubMed database. 
 
Figure 2.8 shows what the screen looks like when uploading a citation file.  About 
two-thirds of the way down the screen there is a grey Browse button that allows 
researchers to select files on their own computers to upload. In this case, a file a 





box, the researcher should next enter all the details about the origin of this file; most 
importantly the search terms used. This information is needed when writing up the results 
of the systematic review. 
Figure 2.8. Uploading a citation file from Cochrane CENTRAL. 
 
While files can be uploaded from any database, Open-Meta has special support 
for PubMed, Cochrane CENTRAL, and the Web of Science databases and will accept 
reference files in the following formats: PMID, MEDLINE (or .nhib), Cochrane 
CENTRAL export format, EndNote Desktop (.ciw), and .ris and .BibTex, one or the other 





Figure 2.9 shows the current list of searches for this project. In this example, the 
first search has been processed, so it can no longer be edited or deleted. The Update 
button would create a duplicate of this search in the list. The duplicate can be used to 
repeat the search at a later date to update the project with citations published since the 
initial search. 
Figure 2.9. Open-Meta’s list of saved and completed searches. 
 
Reviewing Studies 
As soon as a search has been processed, its studies are available for review. In this 
stage of a systematic review, researchers look at each study’s title and abstract to 






Initially, the review feature provides a way to find a specific citation or groups of 
citations by search on a phrase in the title or abstract, an author name, a year of 
publication, or a journal name. Reviews can also be searched by review status over the 
whole project or by review status for the current reviewer. In Figure 2.10, there has been 
a search for blood pressure in the title or abstract. Just above the results we see that four 
articles have been found and none of them have been reviewed yet (the entire page is not 
shown). To review these articles, the reviewer would click one of the green Review 
buttons, and the system would show a page like the one shown in Figure 2.11. 






In Figure 2.11 the reviewer can Fail or Pass the study, as well as Skip forward or 
backward in the list of studies selected in Figure 2.10. The project PI can specify in the 
project’s settings whether a reason code must be checked before Fail is clicked. The 
reason codes shown in Figure 2.11 are the default codes (DNMPC means does not meet 
project criteria), but the PI can replace these with custom codes in the project’s settings. 
Figure 2.11. Reviewing a study to decide if it meets the project’s criteria. 
 
One other interesting feature of the page in Figure 2.11 is the list of Full text links 
on the line after the citation’s year and journal. The PMID link, if available, will open the 





article. The PMCID link, if available, will go directly to the article, as will the DOI link, 
if available. The Google Scholar link, which is always available, will initiate a search for 
the article. These links are not usually needed for this stage of review, but they are very 
helpful when, for example, the abstract is missing. 
Figure 2.11 also shows a submenu with the selections Dashboard, Duplicates, and 
Citation List. The dashboard displays three simple graphs showing the percentage of 
articles that were duplicates; the percentages for not-reviewed versus failed versus 
passed; and for the articles that have failed only, the number of times they have been 
reviewed.  Ideally, multiple reviewers will examine each study, although in the Open-
Meta process, as soon as any reviewer has given an article a pass, that article moves to 
the extraction stage for a more comprehensive review. The Duplicates button leads to an 
unfinished section of the Open-Meta application for identifying duplicate articles. Right 
now the application indentifies duplicates by PMID, but if a publication is not in PubMed 
it won’t have a PMID, so this section needs further work. 
Extracting Data from Studies 
After any reviewer has clicked the Pass button, indicating that the citation meets 
the project’s criteria, the citation is visible in the Open-Meta application’s extraction 
process. 
The Extract menu item has a sub-menu with three items, Dashboard, PICOT 
Setup, and Extraction List, as shown in Figure 2.12. Like the Search and Review menu 
items, the Extract menu item’s Dashboard displays summary data about the project’s 





displays the review status of all citations in the project, while the graph on the right 
displays the extraction status of the citations that have passed the Review process. 






The PICOT Setup submenu, as shown in Figure 2.13, allows project team 
members who have data extraction permission (investigator role and higher) to customize 
the project’s participant groups, interventions, comparisons, outcomes, and time spans. 
This section has its own sub-menu for selecting which study characteristic to customize 
In the figure, Time Spans has been selected. The project team has already added a number 
of time spans in this figure, but is able to add more, if necessary, as the study progresses, 
or to edit or delete an existing time span. 
Figure 2.13. PICOT setup in the extraction process. 
 
The Extraction List submenu leads to a page, shown in Figure 2.14, that is much 
like the citation list shown in Figure 2.10. The major difference is that the extraction list 





project during the Review process. As before, it is possible to search or filter the citations. 
Note that in Figure 2.14 there has been a search for citations that include the word insulin 
in the title or abstract, that there are 43 results, all of which have been reviewed for 
extraction. During this more in-depth Extract review process, nine of the studies failed to 
meet project criteria, while 34 have passed the extraction phase of the project. 
Figure 2.14. Selecting articles for extraction. 
 
Clicking one of the green Extract buttons in Figure 2.14 takes you to the page for 





one figure. Figures 2-15 through 2-18 all show various features of the page for extracting 
data from a study. 
Figure 2.15. The top of the extraction page. 
 
Figure 2.15 shows the top of the page. Like the review page shown in Figure 2.11, 
citation data, including the title, authors, and abstract are displayed, as are the Full Text 
Links for finding the entire article online. The extraction phase requires the complete 
article and these links facilitate the task of obtaining article access. When the project team 
member is working from a university or research library internet connection that will 
display articles the library has access to, such as the Wi-Fi connections at Teachers 
College, the Full Text Links are particularly powerful. 
The first section below this one allows collection of study-level data and is shown 





judging the quality of each study using the questions shown in this section. The PI can 
also add additional questions to this section. To edit this section, the project team member 
clicks the green Edit Study-Level Data button. 
The extraction page shown in Figure 2.16 has two additional sections. In the 
middle, above the green Update Review button, is where the team member will enter a 
final decision on whether this study meets the project’s criteria. Again, the project’s 
customized reason-for-failure codes are available. The team member can also leave 
comments about the decision, which will be helpful if the decision is reviewed. 
The final section at the bottom of Figure 2.16 allows viewing, editing, or creating 
new arms for the study. The Open-Meta application defines an arm as a set of 
interventions, outcomes, and time spans that have the same control group. So only a 
study that separately tracks participant groups or comparisons will have more than one 
arm. For example, a study may separately track participants from different age ranges. 











Figure 2.17. Editing a study arm. 
 
Figure 2.17 shows an arm being edited. When editing any section, the extraction 
screen is replaced with a screen that only allows canceling from or saving that section. 
Typically these forms can include custom questions the project’s PI has added using the 
Customize Data Collection Forms menu shown back in Figure 2.6. This allows the 
collection of additional data about the studies in the project. 
The PI of the project we are looking at in this figure did not use customized 
participant groups or comparisons. Eligible participant group and Eligible comparison 
are the application defaults. However, using the feature shown in Figure 2.13, the PI has 
added the interventions, outcomes, and time spans needed to extract data. Typically these 





the Arm allows selecting the exact interventions and time spans used by the current 
citation. In Figure 2.17, the 800 IU/day intervention and the Baseline and 4 month time 
spans have been selected. 
Figure 2.18. Bottom of the extraction page. 
 
Below the green Edit Arm-Level Data button shown in Figure 2.18, there is a 
form for entering the data extracted from the study that is based on the PICOTs selected 





that have been entered by the project team using Figure 2.13’s PICOT Setup. When a 
different outcome is selected, the form fields will change to blanks if nothing has 
previously been entered for that outcome or the form will show the previous entries, as in 
Figure 2.18. 
The dropdown labeled Outcome is has choices for Continuous, Dichotomous, or 
An Effect Size. The Continuous setting supports the following Data Formats: Means & 
SEs, Means & SDs, Means & Overall SD, t-test t-value, and t-test p-value. The 
Dichotomous setting supports Counts and Proportions. The An Effect Size setting 
supports Cohen’s d, Hedge’s g, Odds Ratio, Log Odds Ratio, Relative Risk, Log Relative 
Risk, Pearson’s r, Cohen’s f, and eta-squared. If necessary, the effect size setting allows 
an effect size resulting from a calculation the application does not natively support to be 
entered. 
If multiple interventions or multiple outcomes have been checked in Figure 2.17, 
the data entry form in Figure 2.18 will expand to include them all. After results for an 
outcome, intervention, and time span have been entered and the Save Results button 
clicked, the effect size for that combination is listed in the results at the bottom of the 
page, as shown in Figure 2.18. The Open-Meta application does not currently support 
selecting which effect size to calculate. It always calculates, saves, and displays the 
results in the Hedge’s g effect size. 
Running a Meta-Analysis 
The Synthesize menu is where we leave systematic reviewing behind for good and 





are complete are Analyze and Forest Plot. Figure 2.19 shows what Analyze looks like. 
The project team can create any number of analyses with selected PICOTs. The blue View 
Analysis button leads to a page where the analysis is set up and displayed. It can be a long 
page if there are lots of PICOTs, as in the example shown in Figure 2.20. 
Figure 2.19. The Analyze submenu of the Synthesize process. 
 
Each analysis has a name, a method, and selected PICOTs from all PICOTs that 
are available for this project. At this time the only meta-analysis method the application 
supports is the dependent effects model. In the example shown in Figures 2-20 (upper 
portion of page) and 2-21 (lower portion of page), virtually all of the PICOTs are selected. 
As you can see, for a large study there can be many of them. In this case only one 





analysis. At the bottom of Figure 2.21 you can see the green button that leads to Edit 
Analysis. 
Figure 2.20. Description of a specific analysis (upper portion). 
 
The actual results of the meta-analysis appear below that button, as shown in 
Figure 2.22. The meaning of these results are explained in other chapters of this 
dissertation. But briefly, the dependent effects model allows multiple interventions, time 
spans, or outcomes to share the same control group. Other meta-analysis methods do not 





intervention, one representative time span, and one representative outcome from each 
study. Obviously, this can lead to biased selections, unlike the dependent effects method, 
which does not require these selections.  







Figure 2.22. Below the analysis settings are the actual result of the analysis. 
 
There are examples of the Forest Plot result in other chapters of this dissertation. 
The other menu items on this page, including the Publish process, are incomplete. 
Publish will eventually make it easy for the project team to download tables, figures, and 
bibliographies related to the project. 
Discussion 
The Open-Meta application is the first freely-available multi-user application for 





remotely like the Open-Meta application. And like the Open-Meta application, it is still in 
beta-test. It is the Cochrane Collaboration’s Rev Man Web (Cochrane Collaboration, 
2018), which has been designed for Cochrane’s own reviewers. 
Innovations 
One of the innovative features of the Open-Meta application is the use of a 
statistical method that includes baseline data when calculating effect sizes. Figure 2.18 on 
page 39 shows an example of the form the application uses to collect this data. The 
pretest-posttest-control group design is a best practice and is commonly used in 
randomized controlled trials. However, very few, if any, online effect size calculators 
incorporate the baseline data for the control and intervention groups in the effect size 
calculation. 
Since participants are assigned to the groups randomly, there is an expectation 
that the groups are equivalent. However, the expectations created by randomization apply 
only over large numbers of participants and over the long run. Given the relatively 
limited number of participants in most controlled trials, it would actually be a surprise if 
the groups were initially equivalent on the outcome measures. This is why baseline data 
are collected to begin with—to determine how different the control and intervention 
groups are on outcome and demographic variables at the beginning of the study. 
In his paper Estimating Effect Sizes From Pretest-Posttest-Control Group Designs, 
Scott B. Morris (2008) notes there is not even agreement among statisticians on how to 
analyze this design when the full data set is available, much less when you only have 





group. When working with the full data set, Morris says, typical analysis options are a t-
test on the group change scores, mixed effects analysis of variance with treatment as a 
between-groups factor and time span as a within-groups factor, analysis of covariance 
with baseline scores as a covariate, or a test of group differences using residualized 
change scores. 
For a meta-analysis, only summary statistics are available in published reports of 
research studies. In this case, Morris says, three methods for determining an effect size 
have been suggested. They all use a Cohen’s d-like formula (outcomeMean – 
baselineMean) / standard deviation) to separately calculate the baseline-to-outcome effect 
sizes for both the treatment and control groups, then they subtract the effect size of the 
control group from the effect size of the treatment group, and finally they multiply that by 
the result of a bias-correction formula. For the first method, the divisor in the effect size 
calculation is not a pooled standard deviation, but just the standard deviation of the 
control group at baseline for the control group effect size, and the standard deviation of 
the intervention group at baseline for the intervention group effect size. 
The second method is similar, but the divisor is the pooled standard deviation of 
the treatment and control groups at baseline and the bias-correction formula is slightly 
different. In the third method, the divisor pools the four standard deviations of the 
treatment and control groups at both baseline and outcome measurement. However, 
because of dependency issues, Morris says, there is not an exact bias correction formula 





Morris proceeds to examine the three methods in detail, using real and synthetic 
data, and reports that method two appears to be the most accurate. I wrote the R code to 
incorporate this method into the Open-Meta application. 
With dependent effects analysis, it becomes possible to have multiple baseline 
groups (control plus one for each intervention). An improved method might pool the 
standard deviations for all these groups, but to my knowledge that has not been 
statistically explored. 
Limitations 
The primary limitation of the application is that it is a single-programmer project. 
To be successful, it needs a team of open-source developers. And, of course, it needs 
users. At the moment, without users, the application has received limited testing. Bugs 
can only be discovered through testing and usage. And they cannot be fixed until they are 
discovered. The application needs attention and interest. 
Expanded awareness of the application and its professional usefulness among the 
public health and nutrition communities of educators, researchers, and policy 
professionals could result in the attention the application needs. Awareness in the meta-
analysis statistical community and those they work with and teach would also be very 
helpful.  
Future directions 
There are several features of the Open-Meta application that are incomplete and 
must be finished: identification of duplicate citations, a system for public commenting, 





related to PRISMA diagrams, sequential analysis, bias plots, and meta-regression, and 
finishing the Publish process.  
There are also necessary improvements—for example, the application should 
provide a method to categorize and sort PICOTs numerically, alphabetically, or 
categorically. It should support entering effects in the original research metrics, such as 
the mm Hg metric used for blood pressure.  The next chapter would have been somewhat 
clearer if that had been part of the original design. 
However, the primary future task is to recruit users. Without users, the application 
has no reason to be. With users, it will also attract open-source programmers and larger 
organizations that want to support it. That is the ultimate goal of the project.  
Conclusion 
The Open-Meta application has the potential to provide health educators with the 
ability to use systematic reviews and meta-analyses to inform the best health care policies. 
It simplifies the review process while making that process totally transparent, allows 
multi-user teams to work on a project simultaneously, and can provide conclusive results. 
Its major weakness at this time is a lack of users, but that may change as people learn 





III – DAILY VITAMIN D3 SUPPLEMENTATION AS A TREATMENT FOR HEALTH 
DISPARITIES IN BLOOD PRESSURE 
It is well-known that high blood pressure is among the many health disparities 
between African- and European-Americans (Berg, 2018). It is less well-known that skin 
color is an evolutionary adaptation to sunlight. Darker skin is more protective against 
intense sunlight than lighter skin, but at the latitude of the U.S., darker skin is less 
effective at producing vitamin D from sunlight than lighter skin colors. Since sunlight is 
the major source of vitamin D in humans, there is also a large racial disparity in vitamin 
D status in the U.S. (Weishaar et al., 2016). Although U.S. racial health disparities are 
rightfully considered to have primarily social causes, in this chapter I will examine the 
biological disparity of vitamin D status as a cause of the racial disparity in blood pressure, 
as well as the potential of daily vitamin D3 supplementation to eliminate this health 
disparity. 
Blood pressure is measured in millimeters of mercury (mm Hg) and is reported as 
two numbers, systolic blood pressure is the higher number and represents the pressure 
when the heart is contracting. Diastolic blood pressure is the lower number and 
represents the minimum pressure while the heart fills with blood. For simplification, this 
report considers only the higher, systolic blood pressure. 
My examination will have two steps. First I will confirm the degree of the 
disparities in systolic blood pressure and vitamin D status by analyzing U.S. nationally-





(NHANES). Second, I will report on the actual effect of daily vitamin D3 
supplementation on systolic blood pressure using a systematic review and meta-analysis 
that combines the results of all randomized controlled trials that have tested this 
intervention. 
Research Questions 
My research questions are: 
1. In a nationally-representative sample of U.S. individuals age 8 and older, 
how large are the systolic blood pressure and vitamin D disparities 
between those individuals who self-identify as non-Hispanic black and 
non-Hispanic white in the U.S.? 
2. Does daily vitamin D3 supplementation have a statistically-significant 
beneficial effect on systolic blood pressure large enough to eliminate this 
disparity? 
Methods 
This study uses only previously published data without identifying information; 
consequently the Institutional Review Board of Teachers College, Columbia University 
ruled this study exempt from review and issued approval 17-220 on March 12, 2017. 
The overall protocol for the systematic review and meta-analysis described here 
was accepted and published by the International Prospective Register of Systematic 





which was used to facilitate this systematic review and meta-analysis, also requires 
entering the proposed protocol as the first step of establishing a new project (Weishaar, 
2018). 
The primary adjustment made to the overall protocol for this dissertation is that 
the overall protocol proposes including all trials with any health or performance outcome. 
This chapter, however, is synthesizing results only from trials that measured blood 
pressure as an experimental outcome. Likewise, the next chapter will examine results 
only from trials that measured markers of diabetes.  
Data Sources 
NHANES study: Research question 1. NHANES collects cross-sectional data 
representative of the non-institutionalized U.S. population in two-year cycles using a 
randomized sampling design called a complex survey that uses both clustering and 
stratification. Data are collected on hundreds of variables from about 5,000 participants 
per year.  
NHANES measures vitamin D status with a blood test for 25-hydroxyvitamin D 
(25(OH)D). However, there are actually two versions of vitamin D, one produced in yeast 
and fungi (vitamin D2) and the other in plants and animals (vitamin D3) (Japelt & 
Jakobsen, 2013). In humans, sunlight produces vitamin D3 in the skin, which is readily 
converted to 25(OH)D3 in the liver. 25(OH)D is strongly attracted to vitamin-D binding 
protein, an albumin-like component in the blood. Consequently, the amount of 25(OH)D3 





D2 and D3 are also found in small amounts in some foods. Over-the-counter supplements 
typically contain vitamin D3, while the vitamin D available by prescription is vitamin D2. 
Vitamin D data was not collected during the first two-year NHANES cycle and 
has not yet been released for the most recent cycles, so this chapter dropped those cycles. 
In addition, the 25(OH)D assay method used before 2007-2008 did not report 25(OH)D2 
and 25(OH)D3 separately. The D2 versus D3 issue becomes visible in a blood pressure 
study, so I dropped the three cycles that did not split them out, leaving the four cycles of 
data collected from 2007 to 2014. 
NHANES measured blood pressure data in all cycles from all participants age 8 
and older. Consequently, in this chapter I dropped all data from participants younger than 
8. The NHANES protocol specifies that blood pressure be measured and reported 
multiple times and averaged by the researcher using a prescribed algorithm (National 
Health and Nutrition Examination Survey, 1999).  
NHANES used a self-report questionnaire to determine participant race and 
ethnicity in all cycles for all ages. Because this study concerns racial health disparities, 
we dropped all data from participants who did not self-identify as non-Hispanic black or 
non-Hispanic white. NHANES collected age and measured body weight in all cycles for 
all participants. 
Systematic review and meta-analysis: Research question 2. The "experimental 
unit" in a meta-analysis is a report of the results from a study. In order to discover 
appropriate reports, I used the Cochrane Central Register of Controlled Trials 
(CENTRAL). Since 1998, Cochrane review groups have completed 11 systematic 





management of asthma, treatment of chronic pain in adults, mortality (twice), cancer 
prevention, fracture prevention, cystic fibrosis, bone mineral density in children, and 
corticosteroid-induced osteoporosis. The most recent study on mortality includes more 
trials than any other vitamin D systematic review ever published. 
CENTRAL contains a record for every study examined in its own reviews. In 
addition, CENTRAL is updated monthly with records of new randomized controlled 
trials retrieved from Medline and EMBASE, from specialized registers created by 
Cochrane's review groups, and from Cochrane's hand search results register. Because of 
the comprehensive nature of CENTRAL's database of randomized controlled trials, 
CENTRAL by itself should provide a systematic view of all relevant randomized 
controlled trials. This avoids the additional work of stage 1 reviews finding duplicative 
results in additional databases that are a mix of randomized controlled trials and other 
types of publications, which made this project feasible for a single author. Complete 
information on the contents of CENTRAL and how it is updated is available (Cochrane 
Library, 2000-2019). 
My search strategy was to use the MeSH descriptor [Vitamin D] explode all trees. 
Preliminary searches found that additional vitamin D-related MeSH terms did not 
increase the number of records returned by CENTRAL. Adding additional vitamin-D 
related text terms vastly increased the number of records returned, but I did not have the 
resources to review that many papers, particularly since almost all would fail stage 1 
review anyhow (these are trials in which vitamin D is mentioned somewhere in the full 
text; the MeSH descriptor identifies trials that are actually about vitamin D). CENTRAL 





An initial download of bibliographic information completed on March 31, 2017, 
returned 2,470 study reports. All of these reports received a stage 1 review. The initial 
search was refreshed on January 10, 2019, which added 1,442 references. The vast 
majority of these new reports were studies recently added to CENTRAL that had been 
proposed at clinicaltrials.gov, an online registry for health-related randomized controlled 
trials. Clinicaltrials.gov is to the randomized controlled trial what PROSPERO is to the 
systematic review and meta-analysis. However, most of these proposed studies have no 
results yet. Because the January 2019 refresh included so many more additional articles 
than expected, only trials from this refresh with "blood pressure" or "hypertension" in the 
title or abstract were reviewed for eligibility in this chapter’s study. 
My protocol also specified that any other vitamin D3 trial not discovered by this 
process should be included in the study. I discovered, either by reference in an existing 
study or by a PubMed search on the clinicaltrials.gov id, 14 additional studies, which I 
added to the database. Of the 3,926 studies added to the Open-Meta application for this 
project, two were duplicates, leaving 3,924 studies. Of these, 1,037 were not reviewed for 
this study because they came from the January 2019 data refresh and did not appear in the 
"blood pressure" or "hypertension" searches, 2,510 failed stage one review, and 377 
moved forward to the stage 2 or extraction function in the Open-Meta application. 
Data Handling 
NHANES study: Research question 1. All of the data used in this study are 
publically available on the NHANES website (National Center for Health Statistics, 





four cycles (2007-2008 through 2013-2014), which are distinguished by filenames 
containing the letters "E" through "H". For each cycle, this study used the files for: 
Demographic Variables and Sample Weights: This file includes, among many 
other variables, variables required for the statistical analysis of a complex survey (strata, 
psu, mobile exam unit (MEC) weight), NHANES cycle, and participant age and 
race/ethnicity. 
Body Measures: This is one of the examination data files, which, among other 
variables, includes body weight in kilograms. 
Blood Pressure: This is another of the examination data files, which includes up to 
four measures of systolic blood pressure for each participant 8 years and older. 
Vitamin D: This is one of the laboratory data files, which includes 25(OH)D2 and 
25(OH)D3 for each participant over age 1 in the included cycles. 
SEQN: Every file includes a “key” column of respondent sequence numbers, 
which are used to match rows in each file with particular participants. The end result after 
data handling is a single table with each eligible participant having a row in the table and 
each variable its own column. 
After dropping cycles without 25(OH)D data split between D2 and D3, dropping 
ages without blood pressure data, dropping participants self-identifying from other 
ethnicities, and dropping cases with missing data on any of the critical variables, the 
dataset consisted of 16,319 unweighted cases (5,603 non-Hispanic black; 10,716 non-
Hispanic white) in 124 complex survey clusters. 
Systematic review and meta-analysis: Research question 2. The Open-Meta 





as well as other bibliographic information and, when available, links to the full text of the 
report. My criteria for inclusion were: 
Study: The study had to be a randomized controlled trial. 
Participants: Any RCT with human participants was allowed. 
Intervention: The only allowable intervention was daily vitamin D3 
supplementation. Many of the studies in the database gave participants vitamin D2; 
vitamin D metabolites, such as 25(OH)D; or vitamin D analogues, which are vitamin D-
like molecules created to be patentable. Other studies used large bolus doses of vitamin 
D3 at weekly or longer intervals. Both of these types of studies were ineligible for 
inclusion in this project. 
Comparison: The comparison group could be no-intervention, placebo, or 
standard-of-care. The comparison groups had to be identical except for the daily dose of 
vitamin D3, so, for example, both groups might also take an equal amount of calcium. 
No-intervention control groups were considered identical to placebo control groups 
receiving no supplementation. Study arms in which the control group received a smaller 
dose of vitamin D3 than the intervention group (typically a standard-of-care control 
group) were accepted. In trials with intervention groups taking different dose sizes, the 
control group for all interventions was the group taking the smallest dose (including 
none). If a control group received vitamin D3, the difference in dose size between the 
control and intervention group was be considered the intervention dose for that arm. 
Outcome: Outcome measures were accepted only if the mean and a variance 
measure of the change in systolic blood pressure between baseline and measurement was 





blood pressure for both of the groups was reported at baseline and at an eligible time 
afterward. In this case the variance of the change score had to be estimated, which is why 
change scores with a variance measure were preferred. Variance is typically reported as a 
standard deviation, standard error, or 95% confidence interval, any of which were 
acceptable. 
Time Span: To be included, the study had to include at least one measure of blood 
pressure four or more weeks after the beginning of the intervention. Outcomes measured 
after treatment ended were ineligible for inclusion in the study. If outcomes were 
measured at multiple eligible time spans, they were all recorded. 
The Open-Meta application makes any study that passes Stage 1 review available 
for data extraction. Baseline and eligible outcome blood pressure measurements of any 
type (normal, 24-hour, central) were recorded for each study. Studies could also fail at 
this stage for subsequent discovery of Stage 1 issues, as well as new issues, such as data 
reported without a measure of variance (usually medians rather than means).  
Statistical Analysis 
Statistical analysis for both studies was done with the statistical programming 
language R, version 3.4.1 (R Core Team, 2017).  For the NHANES study the primary 
additional package was survey, version 2.2 (Lumley, 2004) and for the meta-analysis the 
primary additional package was robumeta, version 2.0 (Fisher, Tipton, & Zhipeng, 2017). 
NHANES study: Research question 1. Each participant in a complex survey 
receives a statistical weight that essentially portrays how many people in the population 





probabilities of selection (some groups are oversampled). I calculated population means 
using the survey package’s svymean function and regressions using its svyglm function. 
For the regressions, the explanatory variables were centered so that the intercept would 
represent the expected systolic blood pressure of a 40-year old non-Hispanic white, 180 
pounds, with a 25(OH)D3 level of 20 ng/ml. 
Systematic review and meta-analysis: Research question 2. Randomization of 
participants to RCT groups creates the expectation that the groups will be exactly the 
same except for the intervention, but with the sample sizes typically used for an RCT this 
is rarely actually the case. Consequently, the Open-Meta application determines the effect 
size of an intervention by calculating the difference between the control and treatment 
groups at both baseline and outcome, then calculating the distance between the 
differences. For example, if the treatment group is 2 units higher than the control group at 
baseline and 5 units higher at outcome, the Open-Meta application calculates the effect 
size of the treatment as 3 units. 
The Open-Meta application also uses the robumeta package’s dependent effects 
method to estimate the combined result of the studies. Robumeta has been shown to 
provide unbiased estimates of dependent outcomes even through the correlations between 
the outcomes are unknown (Moeyaert et al., 2017). All of the other methods typically 
used for meta-analysis, fixed effect, random effects, and mixed effects, do not allow any 
dependency between measures in a single study. For example, if a treatment group’s 
outcome is measured multiple times, these older methods require that only one of those 
times can be included in the analysis. Likewise, if a trial uses multiple treatment doses, 





Allowing a researcher to choose which intervention and which time span to 
include in the meta-analysis can easily lead to bias. Dependent effects analysis, on the 
other hand, robustly estimates the correlations between the variables and allows both 
multiple outcome measurements over time spans and multiple interventions using a 
single control group. Since every measurement from a study is included, there is no 
chance of the researcher selecting the “best” result from the set of results found by a 
study. Robumeta calculates a weight, similar to the weights used by the other meta-
analysis methods, for each study (studies with more participants receive more weight). 
When there are multiple dependent measurements within a study, robumeta distributes 
the study’s weight equally to the different measures. 
Results 
NHANES Study: Research Question 1 
Because the NHANES data were collected and analyzed using complex survey 
techniques with appropriate weights, the results are representative of the U.S. non-
institutionalized population of non-Hispanic blacks and whites, age 8 and older, during 
the 8-year time span beginning in 2007. Individuals in other racial/ethnicity groups and 
children younger than 8 are included in the NHANES data, but were not used in this 
study. 
Table 3.1 shows selected demographics of the nationally-representative data. Both 
the mean and median of systolic blood pressure is 2 mm Hg higher in non-Hispanic 






Selected demographics of non-institutionalized U.S. subpopulations of non-Hispanic-
blacks and whites, age 8 and older, in the 2007-2014 time frame. 




Unweighted n 5,603 10,716 
Systolic Blood Pressure in mm Hg   
 95% of group is higher than: 97 96 
 Median: 118 116 
 95% of group is lower than: 156 149 
 Mean (SD): 121.0 (18.3) 119.0 (16.7) 
25(OH)D3 in ng/ml   
 95% of group is higher than: 7 13 
 Median: 16 28 
 95% of group is lower than: 33 48 
 Mean (SD): 17.5 (8.5) 28.9 (10.4) 
 Regressions centered on: 20 
25(OH)D2 in ng/ml   
 95% of group is higher than: 0.5 0.5 
 Median: 0.5 0.5 
 95% of group is lower than: 5 4 
 Mean (SD): 1.6 (4.8) 1.5(4.5) 
 Regressions centered on: 0.6 
Body weight in pounds   
 95% of group is higher than: 94 102 
 Median: 176 171 
 95% of group is lower than: 284 263 
 Mean (SD): 182.0 (57.9) 175.1 (50.3) 
 Regressions centered on: 180 
Age in years   
 95% of group is higher than: 11 13 
 Median: 37 45 
 95% of group is lower than: 72 79 
 Mean (SD): 38.3 (18.9) 44.4 (20.0) 
 Regressions centered on: 40 
 
whites, while 25(OH)D2 levels are about the same in the two groups and much, much 





are also somewhat younger and somewhat heavier than the non-Hispanic white 
subpopulation. 
Table 3.2 shows four different regression models predicting systolic blood 
pressure in mm Hg. For these regressions, data for 25(OH)D3, 25(OH)D2 , weight, and 
age were centered at 20 ng/ml, .6 ng/ml, 180 pounds, and 40 years of age to put the 
intercept at the center of the data and to make the intercept easier to interpret. The 
omnibus test for each model has a highly significant p value. In each model, the intercept 
estimates the systolic blood pressure of a white participant with the centered value of 
variables included in the regression model. 
The first model simply confirms that, as a subpopulation, non-Hispanic blacks 
have higher blood pressures than non-Hispanic whites by about 2 mm Hg. This is the 
same result we saw in Table 3.1 on page 60 in terms of group means and medians. The 
second model adds 25(OH)D3 status. This regression indicates that a difference of 10 
ng/ml in 25(OH)D3 is associated with a 0.8 mm Hg drop in blood pressure. Note that in 
this model the coefficient for non-Hispanic black is not statistically significant, which can 
lead to the interpretation that, from a correlational perspective, 25(OH)D3 status 
completely moderates, or explains, U.S. racial disparities in systolic blood pressure. 
Model 3 is like model 2, but using 25(OH)D2 instead of D3. In this model, an increase in 
25(OH)D2 is associated with higher, rather than lower, systolic blood pressure. Finally, 
model 4 includes age and weight as well as 25(OH)D3 and shows that a 10-ng/ml change 
in 25(OH)D3 is associated with a larger drop in blood pressure than a 10-pound change in 
body weight. However, a 10-year change in age is associated with a blood pressure 







Predictors of systolic blood pressure in mm Hg in U.S. non-Hispanic blacks and whites 
age 8 and older in the 2007-2014 time frame. 
Predictor Model 1 Model 2 Model 3 Model 4 
Non-Hispanic Black 2.01 ± 0.6*** 1.09 ± 0.6 1.99 ± 0.6*** 3.41 ± 0.5*** 
10 ng/ml 25(OH)D3   -0.8 ± 0.2***  -0.6 ± 0.1*** 
10 ng/ml 25(OH)D2   2.6 ± 0.4***  
10 years age    3.9 ± 0.1*** 
10 pounds weight    0.47 ± 0.03*** 
Intercept
1
 119 ± 0.3*** 120 ± 0.4*** 120 ± 0.4*** 118 ± 0.3*** 
Omnibus test
2
 F(1,63)=12.6*** F(2,62)=19.3*** F(2,62)=38.2*** F(4,60)=1406*** 
R
2
 .002 .004 .007 .264 
1. The intercept can be interpreted as the average blood pressure in mm Hg for white 40-
year olds, weighing 180 pounds, with a 25(OH)D3 level of 20 ng/ml. 
2. The omnibus test used for a complex survey regression is the Wald Test. 
Table shows unstandardized regression coefficients ± their standard error. 
*** p < .001 
 
Systematic Review and Meta-Analysis: Research Question 2 
Table 3.3 presents the results of my systematic review and meta-analysis.  I 
extracted systolic blood pressure data from 30 studies reporting 49 outcomes (some 
studies included multiple vitamin D3 doses, others measured blood pressure multiple 





intercorrelation across the observed effect sizes” (Tanner-Smith & Tipton, 2014). Rho 
was initialized at .8 and a sensitivity analysis (bottom of Table 3.3) determines whether 
the results are robust to other values of Rho. In this case, the effect size, its standard error, 
and the estimate of τ2 are robust to Rho values from 0 to 1. In this analysis, I2, which is 
the ratio of heterogeneity to total variance and which varies from 0 to 1, is relatively low. 
Likewise τ2, which is an estimate of between-study variance and which is in the same 
metric as the effect size (τ un-squared is the standard deviation of the effect size estimate), 
is also low. These low values indicate that the relationship between daily vitamin D3 
supplementation and blood pressure is not wildly affected by the kinds of differences 
there are in these 30 studies in terms of participant characteristics, vitamin D3 dose, time 
span of supplementation, and so on. 
Table 3.3 
Results of meta-analysis of the effect of daily vitamin D3 supplementation on systolic 
blood pressure 
Dependent Effects Model 
(Robust variance estimation for correlated effects with small sample corrections) 
 
Number of studies = 30 
Number of outcomes = 49 (min = 1, mean = 1.63, median = 1, max = 6) 
 
Rho = 0.8 
I.sq = 32.5 
Tau.sq = 0.0198 
 
              Est     SE      t      df      p         95% CI    Sig 
Effect size 0.0971  0.0447  2.172  23.972  0.040  0.00481, 0.189  ** 
--- 




Rho     0       0.2      0.4      0.6      0.8       1 
Effect Size   0.0971   0.0971   0.0971   0.0971   0.0971   0.0971 
Std. Error    0.0447   0.0447   0.0447   0.0447   0.0447   0.0447 






Finally, Table 3.3 shows that when the studies are combined, there is a statistically 
significant positive effect of 0.097, with a 95% confidence interval of [0.005, 0.189], and 
a p-value of .04. The effect size is in units called Hedge’s g and represents the effect size 
in standard deviations of systolic blood pressure. The standard deviation for blood 
pressure over the entire population is not shown in Table 3.1 on page 60, but a similar 
calculation shows that it is 16.87 mm Hg. That gives us an estimate of the effect size of 
daily vitamin D3 supplementation on systolic blood pressure of 0.098 * 16.87 = 1.65 mm 
Hg—a little less than the 2.0 mm Hg racial health disparity in the U.S. for blood pressure. 
Table 3.4 lists all of the studies included in this meta-analysis with relevant facts 
about each study. 
Table 3.4 

































































































(Pan, Wang, Li, Kao, & 
Yeh, 1993) 
L L L L H Systolic BP 200 3 15 14 
(Pfeifer, Begerow, Minne, 
Nachtigall, & Hansen, 
2001) 
L L L L L Systolic BP 800 2 72 73 
(Zittermann et al., 2009) L L L L L Systolic BP 3332 12 83 82 
(Maki et al., 2011) H L L L L Systolic BP 1200 2 29 31 





































































































(Shab-Bidar et al., 2011) L L H L L Systolic BP 1000 3 50 50 










(Larsen, Mose, Bech, 
Hansen, & Pedersen, 
2012) 
L L L L L 24-hour Systolic BP 









(Muldowney et al., 2012) L L L L L Systolic BP 20-40y 
Systolic BP 20-40y 
Systolic BP 20-40y 
Systolic BP 64+ y 
Systolic BP 64+ y 

























(Salehpour et al., 2012) L L L L L Systolic BP 1000 3 38 39 










(Asemi, Samimi, Tabassi, 
Shakeri, & Esmaillzadeh, 
2013) 
L L L L L Systolic BP 400 2 24 24 
(Breslavsky et al., 2013) U L L L H Systolic BP 1000 12 13 19 
(Chai, Cooney, Franke, & 
Bostick, 2013) 
L L L L L Systolic BP Both +Ca 


























& Vaquero, 2013) 










(Wamberg et al., 2013) L L L L L Systolic BP 7000 6 21 22 
(Chen et al., 2014) L L L L L 24-hour Systolic BP 














































































































(Molina et al., 2014) L H H H H Systolic BP 666 6 51 50 
(Mose et al., 2014) L H H H L 24-hour Systolic BP 3000 6 25 25 
(Raja-Khan et al., 2014) U L L L L Systolic BP 12000 3 15 13 
(Arora et al., 2015) L L L L L 24-hour Systolic BP 3600 6 175 188 
(Gepner et al., 2015) L L L L L Systolic BP 2100 6 49 49 
(Pilz et al., 2015) L L L L L 24-hour Systolic BP 2800 2 92 91 
(Bressendorff et al., 
2016) 
L L L L L 24-hour Systolic BP 














(Yin et al., 2016) L U U U L Systolic BP 700 12 62 61 
(Zerofsky, Jacoby, 
Pedersen, & Stephensen, 
2016) 










(Mousa et al., 2017) L L L L L Systolic BP 4000 4 26 28 




















Notes: Risk of Bias ratings are L = Low, H = High, U = Unclear. Dose is in International Units (IU) per 
day. Time Span is the amount of time between supplementation start and outcome measurement in 








Figure 3.1 is a forest plot of the results of the studies included in the meta-analysis. 
The conclusion of almost every study (the ones where the confidence interval line crosses 
zero) was that vitamin D3 does not lower blood pressure, yet combined, the same studies 


































The results of this chapter’s study suggest that in the U.S., those who self-identify 
as non-Hispanic black have higher systolic blood pressure than those who self-identify as 
non-Hispanic white. Overall, this racial difference is small, about 2 mm Hg. Our 
NHANES-based correlational results suggest it would require a change in 25(OH)D 
status of about 25 ng/ml (2 mm Hg / -.8 mm Hg per 10 ng/ml change in 25(OH)D) to 
close the systolic blood pressure gap between blacks and whites, however, the actual 
black-white 25(OH)D gap is about 11 ng/ml. Yet, at the same time, this study’s 
correlational results also indicate that in a statistical sense, the black-white difference in 
25(OH)D status completely moderates, or explains, the gap in blood pressure.  
Results from this chapter’s systematic review and meta-analysis show that daily 
vitamin D3 supplementation has a statistically significant beneficial effect on blood 
pressure. In the mix of studies included in our analysis, this effect was about 1.65 mm Hg. 
These results support the theory that biological differences in skin color lead to biological 
differences in vitamin D3 status, which in turn lead to biological differences in systolic 
blood pressure. In other words, this health disparity is at least in part due to differences in 
vitamin D3 status that can be eliminated with vitamin D3 supplementation. 
Why This Study Contradicts Prior Research 
There have been at least six prior systematic reviews on the effect of vitamin D on 
blood pressure, none of which found an effect. 
Witham and colleagues (Witham, Nadir, & Struthers, 2009)  combined 11 studies, 





not supplement daily, one did not provide a variance estimate). Two of studies from this 
analysis are included here (Pan et al., 1993; Pfeifer et al., 2001). Witham and colleagues 
concluded, “We found weak evidence to support a small effect of vitamin D on blood 
pressure in studies of hypertensive patients.” 
Pittas and colleagues (Pittas et al., 2010) combined 10 studies, eight of which 
were ineligible for the current study (five did not supplement daily, two had invalid 
comparisons (the intervention group was given additional supplements besides vitamin 
D) and one did not provide a variance estimate). Two of the studies from this analysis are 
included here (Pfeifer et al., 2001; Zittermann et al., 2009). Pittas and colleagues 
concluded, “An association between vitamin D status and cardiometabolic outcomes is 
uncertain. Trials showed no clinically significant effect of vitamin D supplementation at 
doses given.” 
Dolinsky and colleagues (Dolinsky, Armstrong, Mangarelli, & Kemper, 2013) 
systematically reviewed 35 studies related to vitamin D and cardiometabolic risk in 
children. Only one of these studies was an RCT. That study (Dong et al., 2010) did not 
provide either a mean or variance estimate for blood pressure but merely reports in the 
text that there were no statistically significant differences. Dolinsky and colleagues 
conclude, “Insufficient evidence was available to conclude that vitamin D 
supplementation yields cardiometabolic benefit.” 
Manousopoulou and colleagues (Manousopoulou, Al-Daghri, Garbis, & Chrousos, 
2015) combined 15 studies, 11 of which were ineligible for the current study (eight did 
not supplement daily and three did not include blood pressure measures). Four of the 





Zittermann et al., 2009). Manousopoulou and colleagues conclude, “This systematic 
review highlights a paucity of interventional studies examining the effects of vitamin D 
status improvement on cardiovascular risk factors among otherwise healthy adults with 
obesity.” 
Beverridge and colleagues (Beveridge et al., 2015) combined 46 studies, 32 of 
which were ineligible for the current study (20 did not supplement daily, ten did not use 
vitamin D3, two did not provide a variance estimate). Fourteen of the studies are included 
here (Breslavsky et al., 2013; Chai et al., 2013; Forman et al., 2013; Gepner et al., 2012; 
Larsen et al., 2012; Muldowney et al., 2012 (2 studies); Pfeifer et al., 2001; Salehpour et 
al., 2012; Shab-Bidar et al., 2011; Toxqui et al., 2013; Wamberg et al., 2013; Wood et al., 
2012; Zittermann et al., 2009). Beverridge and colleagues conclude “Meta-analysis of the 
change in blood pressure between baseline and the final follow-up for each trial revealed 
no clinically or statistically significant effect.” 
Hussin and colleagues (Hussin et al., 2017) combined 16 studies, 13 of which 
were ineligible for the current study (eleven did not supplement daily (and three of those 
did not use D3,) and two did not report variance). Three of the Hussin and colleagues 
studies are included here (Breslavsky et al., 2013; Gepner et al., 2015; Larsen et al., 
2012). Hussin and colleagues concluded, “Vitamin D supplementation did not improve 
endothelial function.” 
This summary of previous studies suggests that to find an effect of vitamin D 






This Study’s Theoretical Model of Vitamin D Action 
The reason eligibility for my study was limited to trials testing daily vitamin D3 is 
related to my conception of the role of vitamin D in humans. Vitamin D is a signaling 
molecule. Its role in whole-body, or endocrine, signaling was discovered first and is all 
many researchers know about vitamin D. In this role, the kidney separates 25(OH)D from 
vitamin D binding protein and, as necessary, coverts it into 1,25(OH)2D. The kidney puts 
both the new 1,25(OH)2D and the remaining 25(OH)D back in the bloodstream, where 
they again rapidly attach to vitamin D binding protein. A few kinds of cells have the 
ability to absorb vitamin D binding protein and to remove the attached vitamin D 
compounds. The level of 1,25(OH)2D in the bloodstream acts to control human calcium 
balance. Bones provide not only structural support but also act as a calcium warehouse, 
the key to which is vitamin D binding protein-bound 1,25(OH)2D. 
However, vitamin D is also involved in cell-to-cell, or paracrine, signaling as well 
as inside-cell, or autocrine, signaling. Deep in their genetic machinery, cells have nuclear 
receptors, which up- and down-regulate specific genes. One of these responds 
specifically to vitamin D and its metabolites. Most models of vitamin D action assume 
that only 1,25(OH)2D can activate this vitamin D receptor, however, it has been shown 
that the precursor 25(OH)D, as well as the breakdown product 24R,25(OH)2D also 
activate the vitamin D receptor and, for the most part, up- and down-regulate different 
genes (Tuohimaa et al., 2013). 
In my conception of the role of vitamin D in humans, however, it is the basic 
sunlight-diet, or parent, form of vitamin D that is absorbed by most cells (Hollis & 





But because the liver rapidly converts this parent form into 25(OH)D, supplementing 
with large bolus doses of vitamin D provides plenty of the parent form for only a day or 
two. Soon the bolus dose is all converted to 25(OH)D and bound to vitamin D binding 
protein, while the quantity of parent vitamin D rapidly drops back to the unsupplemented 
level. Researchers can see the reflection of their bolus dose in a blood test for 25(OH)D, 
but they are not actually giving the participant the equivalent of a daily dose of the 
parental vitamin D. Bolus doses greatly exaggerate parental vitamin D exposure. That is 
why I did not include studies that use them in my analysis. 
Given this model of vitamin D’s action, it also becomes apparent that 
supplementing with the vitamin D metabolites 25(OH)D or 1,25(OH)2D, or with vitamin 
D analogues, will not have a beneficial effect on vitamin D’s autocrine or paracrine 
actions. The reason is that those forms attach to vitamin D binding protein and cannot get 
inside most cells. The parent form of vitamin D, on the other hand, is not as strongly 
attracted to vitamin D binding protein as the vitamin D metabolites and is free to be 
absorbed by cells that do not have the cell-surface structures that absorb vitamin D 
binding protein.  
Likewise, I did not include studies that used vitamin D2 as an intervention because 
I have no reason to expect that a molecule from fungus and yeast will work as well in 
animals as the animal’s own molecule, vitamin D3. 
Limitations 
The glaring weakness of this study is that it was completed by a single researcher. 





each other’s work. In this case, all of the studies from the original search received only a 
single review and worse, the studies found by the update to the original search received a 
review only if the terms “blood pressure” or “hypertension” were in the title or abstract. 
Likewise, a single researcher did all the data extraction. On the other hand, I found more 
than twice as many studies that measured the effect of daily vitamin D3 supplementation 
on blood pressure as the next-larger previous meta-analysis. 
Strengths 
The strengths of this study are that it uses dependent effects analysis to allow the 
inclusion of multiple outcomes, intervention groups, and time spans from the same study, 
which traditional meta-analysis does not allow. It also combines nationally-representative 
correlational data for strong external validity with a dependent effects meta-analysis of 
randomized controlled trials for strong internal validity. Typically researchers have to 
find a balance between external and internal validity and do not get to have both. 
The correlational NHANES data speak to my first research question—average 
racial systolic blood pressure disparities in the U.S. are about 2 mm Hg. Average 
25(OH)D3 disparities are about 12 ng/ml. The systematic review and meta-analysis data 
address my second research question—daily vitamin D3 supplementation does have a 
beneficial effect on systolic blood pressure that, although small, with proper dosing may 






This study supports the hypothesis that skin-color dependent disparities in vitamin 
D status in the U.S. population are a biological determinant of racial health disparities in 
blood pressure. In a nationally-representative sample of U.S. non-Hispanic blacks and 
non-Hispanic whites age 8 and older during 2007-2014, the average systolic blood 
pressure of black participants was about 2 mm Hg higher than white participants. In a 
systematic review and meta-analysis of the effect of daily vitamin D3 supplementation on 
blood pressure, I show that such supplementation has a statistically significant systolic 
blood pressure-lowering effect that could eliminate much or all of this disparity. 
For simplification, the results for diastolic blood pressure were not included in 
this report. Although daily vitamin D3 supplementation also has a statistically significant 
effect on diastolic blood pressure, the effect size is quite small and unlikely to be 
clinically significant. 
Let me emphasize that there is nothing surprising about these findings to those 
who assume that skin color is an evolutionary adaptation to sunlight intensity. From a 
health perspective, that evolutionary adaptation implies that we should expect to find 
health disparities in any population with a variety of skin colors. While U.S. racial health 
disparities are rightfully considered to have social causes, the U.S. public health system 
will never eliminate racial health disparities if it continues to ignore the skin-color-
determined disparity in vitamin D status, which can easily and successfully be eliminated 






IV – DAILY VITAMIN D3 SUPPLEMENTATION AS A TREATMENT FOR HEALTH 
DISPARITIES IN DIABETES 
Much about this chapter is similar to the previous chapter. What will be different 
is that rather than disparities in systolic blood pressure, this chapter will examine 
disparities in the biological markers of diabetes. Unlike before, this chapter will first 
present the systematic review and meta-analysis examining the effect of daily vitamin D3 
supplementation on the markers of diabetes. This meta-analysis demonstrates the 
inclusion of multiple dependent outcomes rather than just one. Next I will discuss some 
of the same markers for diabetes in the U.S. population using data from NHANES. This 
time, however, many of the relationships are non-linear. To capture the maximum amount 
of information from the data, instead of using linear regression, I will use non-linear, 
spline-based regression, which is best understood with figures rather than tables.  
Research Questions 
 My research questions are: 
3. Does daily vitamin D3 supplementation have a statistically-significant 
beneficial effect on the biological markers of diabetes in the U.S. 
population? 
4. If so, do the vitamin D disparities between those who self-identify as non-
Hispanic black and non-Hispanic white in the U.S. seem to account for the 






The Institutional Review Board of Teachers College, Columbia University ruled 
this study exempt from review and issued approval 17-220 on March 12, 2017. 
As detailed in the previous chapter, the overall protocol for the systematic review 
and meta-analysis described here was accepted and published by PROSPERO—the 
International Prospective Register of Systematic Reviews—on April 2, 2017 (Weishaar, 
2017) and in the Open-Meta application (Weishaar, 2018). The primary adjustment made 
to the overall protocol for this chapter’s study is that it is synthesizing results only from 
trials that measured a marker of diabetes as an experimental outcome, rather than any 
reported outcome as specified in the protocol. 
Data Sources 
The data sources for this chapter’s systematic review were exactly the same as 
those described in the last chapter on pages 51 to 54. 
Systematic review and meta-analysis: Research question 3.  As mentioned 
previously, the initial search was refreshed on January 10, 2019, which added 1,442 
references. Because the January 2019 refresh included so many more additional articles 
than expected, for this study, only trials with diabetes, glucose, or insulin in the title or 
abstract were reviewed for eligibility. As before, 377 studies moved forward to the stage 
2 or extraction function in the Open-Meta application. 
NHANES study: Research question 4. In the study presented in the previous 





2014. This was because only those cycles had vitamin D data that split apart vitamin D2 
and vitamin D3. 
In this chapter’s study, on the other hand, our primary interest is markers of 
diabetes. One of those markers, hemoglobin A1c (HbA1c) reports the percentage of a 
certain type of blood molecule that has a sugar attached to it. It is a marker for the 
average blood glucose level over the last two to three months—that is, it is a marker for 
glucose exposure, just as 25(OH)D is a marker for vitamin D exposure. It is also used as 
a diagnostic marker for diabetes. Levels below 5.6% are considered normal, 5.7% to 
6.4% are considered prediabetes, and 6.5% and above indicate diabetes (Pippitt, Li, & 
Gurgle, 2016). HbA1c has been assayed from participant blood draws in all cycles of 
NHANES. NHANES only draws blood for HbA1c from participants age 12 and older, 
consequently I dropped all data from participants younger than 12. 
Two other important markers of diabetes, glucose and insulin, which are also 
measured in blood, require that the participant’s blood be drawn after a period of fasting. 
For a fasting blood test, NHANES draws the participant’s blood in the morning and the 
participants are instructed not to eat anything the day of the test until after the blood draw. 
Because of this requirement, NHANES measures fasting plasma glucose and fasting 
plasma insulin in only one-half of its participants (those who are examined in the 
morning rather than in the afternoon). However, these markers have been measured in all 
cycles. 
Because the fasting blood draws drastically reduces the sample size, for this 
chapter’s study, in addition to the four two-year cycles used in the previous chapter’s 





cycles from 2001 to 2014. Now we cannot distinguish between vitamin D2 and vitamin 
D3, but as we saw in the last chapter, the level of vitamin D2 in most participants is quite 
small compared to the level of vitamin D3. On the other hand, including these cycles 
almost doubles our sample size. 
The studies included in the systematic review often included three other markers 
of diabetes that are not in the NHANES dataset. Homeostatic model assessment is a 
method used to estimate insulin resistance (HOMA-IR) and β-cell function (HOMA-β). 
Insulin resistance means that the body’s cells absorb less glucose for a given level of 
insulin than normal. β-cells, which are in the pancreas, are the body’s insulin-producing 
cells. In Type I diabetes, the β-cells have ceased to function. In Type II diabetes, the rest 
of the body’s cells require increasing amounts of insulin to absorb the same amount of 
glucose. Another marker for insulin resistance is called the Quantitative Insulin 
Sensitivity Index (QUICKI). Although none of these markers are reported in NHANES, 
they can all be calculated from fasting glucose and fasting insulin. I added all three to the 
NHANES dataset using the following formulas. With I as fasting insulin in µU/mL and G 
as fasting glucose in mmol/L: 
HOMA-IR = (I * G) / 22.5 (Wallace, Levy, & Matthews, 2004) 
HOMA-β = (20 * I) / (G - 3.5) (Wallace et al., 2004) 
And, with I as fasting insulin in µU/mL and G as fasting glucose in mg/dL: 
QUICKI = 1 / (log(I) + log(G)) (Katz et al., 2000) 
Again, because this chapter’s study concerns racial health disparities, I dropped 





Hispanic white. NHANES collected age and measured body weight in all cycles for all 
participants. 
Data Handling 
Systematic review and meta-analysis: Research question 3.  Data handling for 
the systematic review was identical to the data handling in the previous study, as 
described on pages 54 to 57, with the exception that the review and extraction search 
terms were diabetes, glucose, and insulin rather than blood pressure and hypertension. 
NHANES study: Research question 4. This chapter’s study used datasets from 
seven cycles (2001-2002 through 2013-2014), which are distinguished by filenames 
containing the letters "B" through "H". In addition to the files used in the previous 
chapter’s study, described on pages 54 and 55, this study included: 
Glycohemoglobin: This is a Laboratory data file, which includes a measure of 
HbA1c for each participant 12 years and older. 
Plasma Fasting Glucose & Insulin: This is also a Laboratory data file, which, in 
addition to measures of glucose and insulin, has a special weight for complex survey 
analysis that expands the half-sample of fasting participants to nationally-representative 
data.  
Vitamin D: For the first three cycles, a value for 25(OH)D in blood is provided in 
nmol/L that does not distinguish between vitamin D2 and vitamin D3. For the four 
remaining cycles, separate values for D2 and D3, again in nmol/L, are provided. Over the 
fourteen-year span, NHANES has used different types of assays for 25(OH)D and has 





converted the value in nmol/L to ng/ml, the metric typically used by U.S. medical 
laboratories, by dividing by 2.4959. For the last four cycles, I converted the D2 and D3 to 
ng/ml separately and then added them together. For D2 the conversion was a division by 
2.4233 and for D3 it was a division by 2.4959. 
For analyses that did not include fasting plasma or fasting glucose, I included all 
participants without missing data and used the complex survey weights appropriate for 
that sample (MEC weights). For analyses that did include fasting plasma or fasting 
glucose, only half the sample was available and I used the complex survey fasting 
weights. 
After dropping cycles without 25(OH)D data, dropping ages without needed 
blood test data, dropping participants self-identifying from other ethnicities, and dropping 
cases with missing data on any of the critical variables, the full dataset consisted of 
28,890 unweighted cases (9,860 non-Hispanic black in 209 complex survey clusters; 
19,030 non-Hispanic white in 213 complex survey clusters). The fasting dataset consisted 
of 13,790 unweighted cases (4,623 non-Hispanic black in 199 complex survey clusters; 
9,167 non-Hispanic white in 212 complex survey clusters). 
Statistical Analysis 
Statistical analysis for both research questions in this chapter was done with the 
statistical programming language R and a variety of add-on packages, as described on 
page 57. 
Systematic review and meta-analysis: Research question 3. The analysis was 





including fasting glucose, fasting insulin, HbA1c, HOMA-IR, and HOMA-β, the sign of 
the effect size was flipped so that better scores on an outcome always resulted in positive 
effect sizes. 
NHANES study: Research question 4. In addition to the packages used in the 
last chapter’s study, the NHANES analysis in this chapter uses the splines package (R 
Core Team, 2017) with linear regression to explore non-linear relationships between 
variables. A “spline” is a curve that can be described mathematically. To use this package, 
I wrapped the predictor variables in the splines function and declared the number of 
splines, or “knots” to use. The splines function creates duplicates of the predictor 
variables for each of the knots. The regression output, which is basically otherwise 
uninterpretable, is then used to predict the dependent variable over the range of a 
predictor variable (in this study, each analysis was limited to a single predictor variable). 
The predicted result, with a 95% confidence interval, can then be graphed. If the graph 
lines are too wiggly, the model has been “overfit” and the statistician reduces the number 
of knots and runs it all again. If the lines seem too straight, the number of knots can be 
increased. The final graphs are based to certain degree on the judgment of the statistician 
as to when a model has the right visual fit. 
Results 
Systematic Review and Meta-Analysis: Research Question 3 
Table 4.1 presents the results of my systematic review and meta-analysis in a 





analysis that included all outcomes. On the following lines, we see the results for the 
individual outcomes, one at a time, from separate analyses. 
I extracted outcomes on eight markers of diabetes from 31 studies reporting 97 
outcomes (most studies included multiple markers of diabetes, one study also included 
multiple vitamin D3 doses, and one study had a single marker and single dose but 
measured the outcome at multiple time points). The diabetes-related outcomes were 
HbA1c, fasting glucose, fasting insulin, HOMA-IR, HOMA-β, QUICKI, and, from a 
study that ran for 24 months, the number of participants beginning diabetes treatment and 
the number developing diabetes (since there is only one study for those two outcomes a 
separate meta-analysis is not possible and Table 4.1 reports on just six individual 
outcomes). 
Figure 4.1 is a forest plot of the results of the studies included in the meta-analysis. 
The conclusion of almost every study (the ones where the confidence interval line crosses 
zero) was that daily vitamin D3 supplementation does not have an impact on markers of 
diabetes, yet combined, the same studies show that there is, in fact, a true, small, 
beneficial effect. 
Table 4.2 lists all of the studies included in this meta-analysis with relevant facts 






















































































































































































































































































































































































































































































































































































































(Patel, Poretsky, & Liao, 
2010) 





















Hu, & Pittas, 2011) 
L L L L L FP Glucose No Ca 
FP Glucose Both +Ca 
HbA1c No Ca 
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(Gabbay, Sato, Finazzo, 
Duarte, & Dib, 2012) 















(Gepner et al., 2012) L L L L L Fasting Plasma Glucose 2500 4 55 55 
(Harris, Pittas, & Palermo, 
2012) 




















(Soric, Renner, & Smith, 
2012) 
L L H L L HbA1c 2000 3 18 19 




















(Belenchia, Tosh, Hillman, 
& Peterson, 2013) 

























































































































































































(Toxqui et al., 2013) L L L L L Fasting Plasma Glucose 









(Wamberg et al., 2013) L L L L L Fasting Plasma Glucose 7000 6 21 22 



































(Ryu et al., 2014) U L L L L Fasting Plasma Glucose 1000 6 65 64 
(Yap et al., 2014) L L L L L Fasting Plasma Glucose 4600 3 80 78 











































































































































































(Foroozanfard et al., 
2017) 




























































Notes: Risk of Bias ratings are L = Low, H = High, U = Unclear. Dose is in International Units (IU) per 
day. Time Span is the amount of time between supplementation start and outcome measurement in 
months. The last two columns show the number of participants in the control and intervention groups. 
 
NHANES Study: Research Question 4 
Because the NHANES data were collected and analyzed using complex survey 
techniques with appropriate weights, the results are representative of the U.S. non-
institutionalized population of non-Hispanic blacks and whites, age 12 and older, during 
the 14-year time span from 2001 to 2014. Individuals in other racial/ethnicity groups and 
children younger than 12 are included in the NHANES data, but were not used in this 
study. 
Figures 4.2, 4.3, and 4.4 are based on the full (not fasting) dataset and show the 





diabetes.  Individuals with HbA1c levels over 6.5% are considered to have diabetes while 
levels between 5.7% and 6.5% result in a diagnosis of pre-diabetes. 
 
Figure 4.2. Impact of age on mean HbA1c percentage. 
 
In these figures, the darker line presents data for non-Hispanic blacks and the 
lighter line for non-Hispanic whites. The lines show both the actual mean and the 95% 
confidence interval for the mean. Where the 95% confidence interval is wider there are 
fewer participants with those characteristics in the NHANES data. Where the lines 





confirms that at all ages there is a health disparity in HbA1c levels and that blacks are 
likely to become pre-diabetic 16 years before whites. 
 
Figure 4.3. Impact of weight on mean HbA1c percentage. 
 
Figure 4.3 shows the impact of weight on HbA1c status. Again we see a health 
disparity. Blacks, on average, are likely to become pre-diabetic at about 180 pounds, 






Figure 4.4. Impact of vitamin D exposure on mean HbA1c percentage. 
 
Figure 4.4 shows that for non-Hispanic whites, HbA1c percentages decline as 
vitamin D status increases. For non-Hispanic blacks, on the other hand, HbA1c 
percentages increase with higher vitamin D levels. The very wide confidence interval for 
blacks at higher vitamin D levels reflects the fact that there are very few non-Hispanic 







Figure 4.5. Relationship of mean fasting glucose and fasting insulin scores with HbA1c. 
 
Figures 4.5 though 4.8 are based on the fasting subsample of NHANES. The 
results are still nationally-representative because the fasting complex survey weights 
were used in these analyses. The figures show mean fasting glucose (upper lines) and 
fasting insulin (lower lines) by HbA1c in Figure 4-5, by age in Figure 4-6, by weight in 
































Systematic Review and Meta-Analysis: Research Question 3 
Although it is more typical for a systematic review and meta-analysis to examine 
a very specific outcome with a variety of interventions, it is not unusual to combine a 
variety of related outcomes for one specific intervention as I have done here. In fact, the 
very first systematic review and meta-analysis combined multiple outcomes (Smith & 
Glass, 1977). 
The first row of Table 4.1 shows that the combined outcomes have a small but 
statistically-significant effect size of 0.220, p = .012, with a 95% confidence interval of 
[0.052, 0.387]. The effect size is in units called Hedge’s g and represents the effect size in 
standard deviations of the comingled scores for the diabetes markers. The signs of the 
effect sizes on markers for which lower scores indicate better health were reversed so that 
beneficial effects are always positive. A Hedge’s g effect of 0.220 is considered small, but 
it is more than double the size of the effect we saw for systolic blood pressure in the 
previous chapter’s study. In the analyses for individual outcomes, the two outcomes 
related to glucose, HbA1c and fasting glucose, are not statistically significant. However 
the three related to insulin, fasting insulin and the markers for insulin sensitivity, HOMA-
IR and QUICKI, are all statistically significant. 
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pressure were much smaller. These large values mean the results of the individual studies 
are heterogeneous (inconsistent or all over the place). Moreover, the heterogeneity does 
not go away when we look at the outcomes one-by-one. 
When heterogeneity is high in meta-analysis, it is appropriate to investigate 
whether the heterogeneity can be explained. For example, perhaps it is related to dose 
size or to baseline 25(OH)D, or to the age of the participants in each study. When that 
kind of data is available for each study, we can use a statistical method called meta-
regression to search for the sources of the heterogeneity. In this case, the Open-Meta 
application has not matured enough to collect these additional data points on each study. 
Moreover, the results of the NHANES part of this study are enlightening in this respect. 
But it is clear that the answer to research question 3, does daily vitamin D3 
supplementation have a statistically-significant beneficial effect on the biological markers 
of diabetes in the U.S. population, is yes, it does. 
NHANES Study: Research Question 4 
Figures 4.2, 4.3, and 4.4 all have HbA1c on the y-axis. Figure 4.2 shows the mean 
HbA1c percentage for non-Hispanic blacks and whites by age. At every age there is a 
health disparity between the groups. The graph points out that on average, a non-Hispanic 
black’s HbA1c percentage will indicate pre-diabetes at age 41, while for non-Hispanic 
whites this happens 16 years later, at age 57. 
Figure 4.3 shows the same analysis in terms of weight. On average, a non-
Hispanic black’s HbA1c percentage will indicate pre-diabetes at about 180 pounds, while 





graph, note how the 95% confidence intervals of the two groups overlap at low weights. 
This indicates there is no statistically significant difference between the groups until 
weight exceeds about 125 pounds. 
Figure 4.4 shows the same analysis in terms of vitamin D exposure. This figure is 
the most remarkable of the figures in this analysis. It clearly shows that for non-Hispanic 
whites, a diagnosis of pre-diabetes is associated only with very low vitamin D levels and 
the association decreases as vitamin D exposure increases. For non-Hispanic blacks, on 
the other hand, increasing vitamin D exposure is associated with an increasing likelihood 
of a diagnosis of pre-diabetes. This is the kind of finding that suggests an explanation for 
the heterogeneity in our meta-analysis results. There are few non-Hispanic blacks with 
25(OH)D levels over 30 ng/ml, but the 95% confidence intervals take that into account. 
Could there be something different about non-Hispanic blacks with 25(OH)D levels that 
high, something unrelated to vitamin D, that is associated with an increased risk for 
diabetes? Or is there something different about non-Hispanic whites with 25(OH)D levels 
that high, something unrelated to vitamin D, that is a associated with a reduction in the 
risk for diabetes? To tease out answers to these questions, we would need to do a meta-
analysis on the effect of daily vitamin D3 supplementation on diabetes using only studies 
in which all of the participants were African Americans. But at the moment there are not 
enough studies like that to do a meta-analysis. 
Figures 4.5 though 4.8 all have fasting glucose and fasting insulin on the y-axis. 
Figure 4.5 shows the mean values for glucose and insulin across the diagnostic values of 
HbA1c. In this figure, note that the lines for insulin completely overlap for non-Hispanic 





reach diagnostic levels for pre-diabetes with lower mean blood glucose than whites. But 
what does this mean? At one extreme, perhaps non-Hispanic blacks, on average, do a 
stricter pre-blood draw fast. At the other extreme, perhaps the HbA1c diagnostic criteria 
should vary by race, with non-Hispanic blacks entering pre-diabetes at a higher HbA1c 
percentage than whites. In any case, the lower mean fasting glucose scores for non-
Hispanic blacks across mean HbA1c percentages is unexpected.  
Figures 4.6 and 4.7, which show mean glucose and insulin values by age and 
weight, suggest that for both glucose and insulin the means for the two groups are very 
close together, although not completely overlapping. In these two figures there is little 
evidence for any diabetes-related health disparity at all. 
Finally, in Figure 4.8, we see glucose and insulin levels over vitamin D exposure 
in the two groups. As in Figure 4.4, we again see that for non-Hispanic whites, higher 
exposure to vitamin D is associated with better glucose and insulin levels. But this 
relationship does not hold for non-Hispanic blacks. These relationships are difficult to 
interpret, but, in part, may indicate why there is so much more heterogeneity in the meta-
analysis of the effect of daily vitamin D3 supplementation on markers of diabetes than in 
the similar meta-analysis on blood pressure. 
The only viable answer to our remaining research question, do the vitamin D 
disparities between those who self-identify as non-Hispanic black and non-Hispanic 
white in the U.S. seem to account for the health disparities we find in diabetes, is that we 





Limitations and Strengths 
As noted in the previous chapter, the glaring limitation of the systematic review 
and meta-analysis it was done by a single reviewer rather than by a team, using software 
which is new and which has not been thoroughly tested.  
The strengths of this study are that it combines nationally-representative 
correlational data with a dependent effects meta-analysis of controlled trials. Dependent 
effects meta-analysis allows the inclusion, from a single study, of multiple intervention 
groups, outcomes, and time-separated outcome measurements that all depend on the 
study’s single control group. Yet without the insights provided by the NHANES 
correlational data, the study in this chapter would have reached the conclusion that daily 
vitamin D3 supplementation would help eliminate health disparities in diabetes. With this 
additional data, we realize the situation is more complex than it appears, and we just do 
not know what the impact of additional vitamin D3 exposure would be on the U.S. health 
disparities in diabetes. 
Conclusion 
The structured review and meta-analysis of controlled trials in this chapter’s study 
supports the hypothesis that daily vitamin D3 supplementation has a beneficial effect on 
markers for diabetes. However, our examination of nationally-representative correlational 
data from NHANES shows very different responses to vitamin D exposure in non-





non-Hispanic whites, it is not clear whether it helps non-Hispanic blacks nor whether it 
would help to diminish the U.S. racial health disparity in diabetes. 
  Future studies should begin with the correlational data to develop theories of 
why vitamin D exposure appears to have the opposite impact on diabetes in non-Hispanic 
whites and blacks. Those theories can then be tested with experimental studies, which of 





V – CONCLUSION 
In the Introduction I listed three specific aims of this project. In this chapter I will 
review the results for each of these three specific aims, identify the limitations and 
strengths of the findings for each specific aim, and address the implications of these 
findings for research and practice. 
Review of Specific Aims 
Specific Aim 1 
To develop a health education-focused, multi-user, open-source application for 
continuous online updating and replication of systematic reviews and meta-analyses. 
Chapter II, The Open-Meta Application, describes the development and status of 
this application. Although a project like this can be continuously improved and, thus, is 
never complete, the application has developed to the point that it can be used to 
efficiently complete a bona fide systematic review and meta-analysis. It is health-
education focused, multi-user, and open-source. Continuous online updating and 
replication are possible but have not yet been demonstrated with actual projects. The 
application’s availability will continue upon completion of this dissertation. 
Limitations. The application has two major types of weaknesses. One type 
pertains to missing features. The other type pertains to missing popularity and usage. 
Missing features include some related specifically to meta-analysis: PRISMA 





more comprehensive system for identifying duplicate citations, a system for public 
commenting, and a better system for dealing with multiple publications reporting 
different outcomes from a single study. There are also issues related to cleaning up the 
database in the extraction phase when “negative” actions take place, such as changing a 
citation from pass to fail, or removing a PICOT from an arm, or removing an arm from a 
study. I am committed to adding these and additional features as part of a continuous 
improvement process for the application. 
The second type of weakness relates to a lack of users and developers. Long term 
survival of the application will require recruiting both users and developers and 
encouraging them to recruit additional users and developers in a viral process. The 
upcoming release of the Cochrane Collaboration’s RevMan Web (Cochrane Collaboration, 
2018) will create major competitive pressure, while also endorsing the need for this type 
of application. 
Neither of these limitations, fortunately, is necessarily permanent. My next steps 
for this project are to add missing functionality to the Open-Meta application while 
expanding its use. I plan to work with professors and librarians to encourage students to 
learn about and use the application. Much of the work of a structured review relies on 
skills that librarians have already developed, making the Open-Meta application 
something that libraries may be interested in sponsoring. At the same time, existing 
organizations that promote the use of structured reviews and meta-analyses may be 






Strengths. At the same time, the Open-Meta application has some considerable 
strengths. First, other than RevMan Web, there is nothing else like it. Unlike RevMan Web, 
the Open-Meta application is open-source and open in the sense that anyone can start or 
join a project. Cochrane also sponsors Cochrane Crowd (Cochrane Collaboration, 2016), 
which by name appears to be similar to the Open-Meta application, but is actually limited 
to crowd sourcing the identification of randomized controlled trials, just one of the 
aspects of the Open-Meta Reviewer role. 
The Open-Meta application operationalizes the PRISMA process, from the 
writing and online publication of a protocol at the beginning of a project to supporting 
PRISMA-compliant publication. RevMan Web does not appear to incorporate publication 
of protocols nor does it allow anyone with an interest to join a project. 
Another major advantage of the Open-Meta application is its reliance on and 
support for dependent effects analysis. The automatically-customized form that Open-
Meta uses to collect data in the extraction phase (see Figure 2.18 on page 39) expands to 
include all interventions and time spans related to a single control group, as defined in the 
settings for a study arm (see Figure 2.17 on page 38). The Open-Meta application is the 
only resource where this type of form is available. 
The exclusive availability of this type of form results from the lack of its need 
with the meta-analysis methods of fixed effects, random effects, and mixed effects. With 
these methods, dependency of several measures on a single control group is not allowed, 
so there is no such form. Like Open-Meta itself, dependent effects analysis does not 






Implications for Practice. The Open-Meta application makes it much easier for 
students to learn how to complete and for teams of even graduate students to actually 
complete systematic reviews and meta-analyses. This helps to inform evidence-based 
practice in health education and other fields. Moreover, the systematic review provides a 
methodology for students to develop familiarity with the academic literature in selected 
areas of study, which is the first step to developing true expertise. An additional benefit is 
the ability to take full advantage of the research base that already exists, which is often 
underutilized. 
My intention is to continue developing the Open-Meta application and to continue 
to use it to create systematic reviews and meta-analyses. If other researchers become 
interested in it, I could either set up a non-profit organization to provide the application 
with a home and long-term support. Another option would be to transfer it to an existing 
organization that could provide the support the application requires. 
In either case, the application can be used by those in health, nutrition, education, 
and other fields to develop gold-standard data their profession can rely on. The 
application could also be used to train students about the details of PRISMA, structured 
reviews, and the statistical fine points of meta-analysis. The more students who are 
trained using Open-Meta, the more users it will have and the more attention it will 
receive.  
Specific Aim 2 
To use this application to calculate the best current estimate of whether daily 





Chapter 3, Daily Vitamin D3 Supplementation as a Treatment for Health 
Disparities in Blood Pressure, addresses this specific aim. The conclusion of that chapter 
is that daily vitamin D3 supplementation does have a small but significant effect on blood 
pressure. While the effect is not large enough to use vitamin D3 as a blood pressure drug, 
it does appear large enough to reduce, but not eliminate, health disparities in blood 
pressure. 
Limitations. The major weakness of this study is that the systematic review and 
meta-analysis was completed by a single researcher. Because of a lack of resources, only 
one research database, Cochrane CENTRAL, was searched for articles and those were 
reviewed for project criteria only once. Some articles found by the January update 
weren’t reviewed at all if they did not have the words blood pressure or hypertension in 
the title or abstract. Nonetheless, no previous review found as many trials of daily 
vitamin D3 supplementation with a measured blood pressure outcome as this one. 
Strengths. The strengths of this study fall in two major areas. First, the study was 
theory-driven, as explained in the section, This Study’s Theoretical Model of Vitamin D 
Action, on pages 72-73. The research literature is full of correlational studies that show 
an association between vitamin D and health and randomized controlled trials that are not 
effective. This study explains why. First, as this study’s theoretical model suggests, 
studies of “vitamin D supplementation” must restrict themselves to daily supplementation 
only with vitamin D3. Second, as this study’s systematic review and meta-analysis 
suggest, the effect, while statistically significant, is too small for trials with limited 





The second strength of this study is that it combines strong external validity, using 
nationally-representative correlational data, with strong internal validity, using a meta-
analysis of randomized controlled trials. In addition, the meta-analysis used dependent 
effects analysis, which allowed including multiple outcomes, interventions, and time 
spans from the same study. 
Specific Aim 3 
To use this application to calculate the best current estimate of whether daily 
vitamin D3 supplementation has a beneficial effect on markers of diabetes, such as fasting 
glucose and fasting insulin, glycosylated hemoglobin (HbA1c), homeostatic model 
assessment for insulin resistance (HOMA-IR) and β-cell function (HOMA-β), and the 
quantitative insulin-sensitivity check index (QUICKI). 
Chapter 4, Daily Vitamin D3 Supplementation as a Treatment for Health 
Disparities in Diabetes, addresses this specific aim. The findings of the study were that 
daily vitamin D3 supplementation has a statistically significant beneficial effect on 
markers of diabetes overall as well as on specific markers related to insulin resistance but 
not specific markers related to glucose levels. However, the correlational part of this 
study raised questions about whether these effects occurred equally in both non-Hispanic-
whites and blacks. 
Limitations. In addition to all the weaknesses listed above for Specific Aim 2, 
this study has the weakness that the findings do not support the vitamin D theories that 
are the basis of this dissertation and that are discussed in the introductory chapter’s 





theory require that the theory be refined or abandoned. This particular theory has enough 
research support that abandonment seems unnecessary, but at this time I have no 
theoretical explanation for the findings. A stronger, future study will. 
Strengths. This study has all of the strengths listed above for Specific Aim 2. It 
also shows why the combination of correlational and experimental data in the same study 
is a strength. Without the NHANES correlational data, this study would have concluded 
that daily vitamin D3 supplementation is indeed a treatment for health disparities in 
diabetes. With that correlational data, however, this conclusion is not possible. While at 
the moment the results of this study do not fit the expected pattern, there is a pattern there 
somewhere that we just have to find, but have not found yet. 
Conclusion 
In 2014, the Cochrane Collaboration released a major systematic review and 
meta-analysis titled Vitamin D supplementation for prevention of mortality in adults 
(Bjelakovic et al., 2014). The following comes from the results section of the article’s 
abstract: 
Vitamin D decreased mortality in all 56 trials analysed together….When different 
forms of vitamin D were assessed in separate analyses, only vitamin D3  
decreased mortality….Trial sequential analysis supported our finding regarding 
vitamin D3, with the cumulative Z-score breaking the trial sequential monitoring 
boundary for benefit, corresponding to 150 people treated over five years to 
prevent one additional death (p. 2). 
Although the researchers did a separate analysis of vitamin D3 supplementation, 
they did not do a similar analysis removing studies that used bolus dosing, which would 





analysis favored vitamin D3 supplementation for the prevention of mortality, the 
conclusion of the study was not that vitamin D3 is safe and effective for improving health, 
but that “further placebo-controlled randomized trials seem warranted” (p. 2). 
In this dissertation I have shown that there is a statistically-significant causal 
effect of daily vitamin D3 supplementation that supports the existence of a causal 
relationship in the correlational data on vitamin D found in nationally-representative 
studies like NHANES by using systematic review and meta-analysis. 
The vitamin D literature’s discordant results are, in part, a result of the assumption 
that vitamin D2 and vitamin D3 are equally effective, although we were warned over a 
decade ago that they are not (Houghton & Vieth, 2006). They are a result, in part, of the 
false assumption that 25(OH)D is a measure of effectiveness rather than exposure and of 
the false assumption that what happens with vitamin D in the human system for calcium 
balance is the end of the vitamin D story. The best assumption we have is that the parent 
form of vitamin D3, produced by sunlight in the skin and obtained through the diet, 
including by supplementation, is absorbed by cells throughout the body and is used as a 
signaling molecule to regulate specific genes to the benefit of human health. 
Health educators, nutritionists, and other public health professionals and 
institutions will not eliminate health disparities until they begin to make correct 
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